PAVmed (PAVM) 10-Q 13 Nov 24 2024 Q3 Quarterly report Financial data

Cover

Cover - $ / shares	9 Months Ended
	Sep. 30, 2024	Nov. 11, 2024
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Sep. 30, 2024
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2024
Current Fiscal Year End Date	--12-31
Entity File Number	001-37685
Entity Registrant Name	PAVMED INC.
Entity Central Index Key	0001624326
Entity Tax Identification Number	47-1214177
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	360 Madison Avenue
Entity Address, Address Line Two	25th Floor
Entity Address, City or Town	New York
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	10017
City Area Code	(917)
Local Phone Number	813-1828
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding	10,985,841	11,068,566
Entity Listing, Par Value Per Share	$ 0.001
Common Stock, $0.001 par value per share [Member]
Title of 12(b) Security	Common Stock, $0.001 par value per share
Trading Symbol	PAVM
Security Exchange Name	NASDAQ
Series Z Warrants, each to purchase 1/15th of one share of Common Stock [Member]
Title of 12(b) Security	Series Z Warrants, each to purchase 1/15th of one share of Common Stock
Trading Symbol	PAVMZ
Security Exchange Name	NASDAQ

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Current assets:
Cash	$ 765	$ 19,639
Accounts receivable	16	61
Inventory	6	278
Prepaid expenses, deposits, and other current assets	1,343	4,520
Total current assets	2,130	24,498
Fixed assets, net	216	1,783
Operating lease right-of-use assets	2,618	4,267
Intangible assets, net		1,424
Equity method investment - at fair value	25,511
Other assets	75	1,147
Total assets	30,550	33,119
Current liabilities:
Accounts payable	465	1,786
Accrued expenses and other current liabilities	4,543	6,626
Operating lease liabilities, current portion	499	1,565
Senior Secured Convertible Notes - at fair value	32,050	44,200
Total current liabilities	37,557	54,177
Operating lease liabilities, less current portion	2,380	2,960
Total liabilities	39,937	57,137
Commitments and contingencies (Note 9)
Stockholders’ Equity:
Preferred stock, $0.001 par value. Authorized, 20,000,000 shares; Series B Convertible Preferred Stock, par value $0.001, issued and outstanding 1,385,149 at September 30, 2024 and 1,305,213 shares at December 31, 2023	3,232	2,993
Common stock, $0.001 par value. Authorized, 50,000,000 shares; 10,660,394 and 8,578,505 shares outstanding as of September 30, 2024 and December 31, 2023, respectively	11	9
Additional paid-in capital	248,200	237,600
Accumulated deficit	(256,312)	(294,433)
Total PAVmed Inc. Stockholders’ Equity (Deficit)	(4,869)	(53,831)
Noncontrolling interests	(4,518)	29,813
Total Stockholders’ Equity (Deficit)	(9,387)	(24,018)
Total Liabilities and Stockholders’ Equity (Deficit)	$ 30,550	$ 33,119

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2024	Dec. 31, 2023
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	20,000,000	20,000,000
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	50,000,000	50,000,000
Common stock, shares outstanding	10,660,394	8,578,505
Series B Convertible Preferred Stock [Member]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares issued	1,385,149	1,305,213
Preferred stock, shares outstanding	1,385,149	1,305,213

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands		3 Months Ended		9 Months Ended
		Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Income Statement [Abstract]
Revenue		$ 996	$ 791	$ 2,985	$ 1,403
Operating expenses:
Cost of revenue		1,381	1,779	4,792	4,809
Sales and marketing		2,920	4,016	11,472	12,893
General and administrative		6,649	6,858	20,337	23,916
Amortization of acquired intangible assets		82	505	559	1,516
Research and development		1,542	3,161	5,125	10,681
Total operating expenses		12,574	16,319	42,285	53,815
Operating loss		(11,578)	(15,528)	(39,300)	(52,412)
Other income (expense):
Interest income		70	124	252	408
Interest expense		(12)	(159)	(38)	(570)
Gain on deconsolidation of subsidiary		72,287		72,287
Change in fair value - equity method investment		407		407
Change in fair value - Senior Secured Convertible Notes		240	(4,392)	(2,488)	(5,772)
Loss on issue and offering costs - Senior Secured Convertible Note					(1,186)
Debt extinguishments loss - Senior Secured Convertible Notes		(1,403)	(1,764)	(2,535)	(3,032)
Debt modification expense				(2,000)
Change in fair value - derivative liability			(31)		(291)
Management fee income		700		700
Gain on sale of intellectual property					1,000
Other income (expense), net		72,289	(6,222)	66,585	(9,443)
Income (loss) before provision for income tax		60,711	(21,750)	27,285	(61,855)
Provision for income taxes
Net income (loss) before noncontrolling interests		60,711	(21,750)	27,285	(61,855)
Net loss attributable to the noncontrolling interests		3,688	4,079	11,075	11,716
Net income (loss) attributable to PAVmed Inc.		64,399	(17,671)	38,360	(50,139)
Less: Series B Convertible Preferred Stock dividends earned		(83)	(77)	(244)	(226)
Less: Deemed dividend on Subsidiary Preferred Stock attributable to the noncontrolling interests				(7,496)
Net income (loss) attributable to PAVmed Inc. common stockholders		$ 64,316	$ (17,748)	$ 30,620	$ (50,365)
Per share information:
Net income (loss) per share attributable to PAVmed Inc. common stockholders – basic	[1]	$ 6.43	$ (2.38)	$ 3.30	$ (7.23)
Net income (loss) per share attributable to PAVmed Inc. common stockholders – diluted	[1]	$ 1.44	$ (2.38)	$ 0.79	$ (7.23)
Weighted average common shares outstanding, basic		10,005,379	7,462,751	9,286,999	6,967,764
Weighted average common shares outstanding, diluted		44,475,638	7,462,751	43,069,449	6,967,764
[1]- Convertible preferred stock and restricted stock awards would potentially be considered a participating security under the two-class method of calculating net income (loss) per share. For periods where losses are presented, such holders are not contractually obligated to share in the losses, there is no impact on the Company’s net income (loss) per share calculation for the periods indicated.

Condensed Consolidated Statem_2

Condensed Consolidated Statement of Changes in Stockholders' Equity (Deficit) (Unaudited) - USD ($) $ in Thousands	Preferred Stock [Member] Series B Convertible Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Treasury Stock, Common [Member]	Noncontrolling Interest [Member]	Total
Balance at Dec. 31, 2022	$ 2,695	$ 6	$ 216,195	$ (228,169)	$ (408)	$ 20,615	$ 10,934
Balance, shares at Dec. 31, 2022	1,205,759	6,300,703
Balance at Jun. 30, 2023	$ 2,841	$ 7	226,423	(260,783)		30,682	(830)
Balance, shares at Jun. 30, 2023	1,254,497	7,235,867
Balance at Dec. 31, 2022	$ 2,695	$ 6	216,195	(228,169)	(408)	20,615	10,934
Balance, shares at Dec. 31, 2022	1,205,759	6,300,703
Dividends declared - Series B Convertible Preferred Stock	$ 221			(221)
Dividends declared - Series B Convertible Preferred Stock, shares	73,842
Issue common stock - PAVM ATM Facility			1,166				1,166
Issue common stock - PAVM ATM Facility, shares		155,384
Vest - restricted stock awards
Vest - restricted stock awards, shares		6,666
Conversions - Senior Secured Convertible Note		$ 2	8,409				8,411
Conversions - Senior Secured Convertible Note, shares		1,358,896
Conversions - subsidiary common stock - Senior Secured Convertible Note						167	167
Impact of subsidiary equity transactions			1,984			(1,984)
Issuance - vendor service agreement			600			147	747
Issuance - vendor service agreement, shares		100,000
Stock-based compensation - PAVmed Inc.			3,266				3,266
Net Loss				(50,139)		(11,716)	(61,855)
Purchase - Employee Stock Purchase Plan			198		60		258
Purchase - Employee Stock Purchase Plan, shares		45,892
Purchase - subsidiary common stock - Employee Stock Purchase Plan						551	551
Stock-based compensation - subsidiaries			876			5,029	5,905
Issuance - subsidiary common stock - Committed Equity Facility, net of financing charges						284	284
Issuance - subsidiary common stock - Settlement APA-RDx - Installment Payment						713	713
Issuance - subsidiary preferred stock (Series A)						13,625	13,625
Treasury stock			(348)		348
Treasury stock, shares		12,589
Balance at Sep. 30, 2023	$ 2,916	$ 8	232,346	(278,529)		27,431	(15,828)
Balance, shares at Sep. 30, 2023	1,279,601	7,980,131
Balance at Dec. 31, 2022	$ 2,695	$ 6	216,195	(228,169)	(408)	20,615	10,934
Balance, shares at Dec. 31, 2022	1,205,759	6,300,703
Balance at Dec. 31, 2023	$ 2,993	$ 9	237,600	(294,433)		29,813	(24,018)
Balance, shares at Dec. 31, 2023	1,305,213	8,578,505
Balance at Jun. 30, 2023	$ 2,841	$ 7	226,423	(260,783)		30,682	(830)
Balance, shares at Jun. 30, 2023	1,254,497	7,235,867
Dividends declared - Series B Convertible Preferred Stock	$ 75			(75)
Dividends declared - Series B Convertible Preferred Stock, shares	25,104
Conversions - Senior Secured Convertible Note		$ 1	3,988				3,989
Conversions - Senior Secured Convertible Note, shares		723,998
Conversions - subsidiary common stock - Senior Secured Convertible Note						167	167
Impact of subsidiary equity transactions			651			(651)
Stock-based compensation - PAVmed Inc.			978				978
Net Loss				(17,671)		(4,079)	(21,750)
Purchase - Employee Stock Purchase Plan			76				76
Purchase - Employee Stock Purchase Plan, shares		20,267
Stock-based compensation - subsidiaries			230			1,037	1,267
Purchase - majority-owned subsidiary common stock - Employee Stock Purchase Plan						275	275
Balance at Sep. 30, 2023	$ 2,916	$ 8	232,346	(278,529)		27,431	(15,828)
Balance, shares at Sep. 30, 2023	1,279,601	7,980,131
Balance at Dec. 31, 2023	$ 2,993	$ 9	237,600	(294,433)		29,813	(24,018)
Balance, shares at Dec. 31, 2023	1,305,213	8,578,505
Balance at Jun. 30, 2024	$ 3,151	$ 10	243,524	(320,630)		55,303	(18,642)
Balance, shares at Jun. 30, 2024	1,357,976	9,554,381
Balance at Dec. 31, 2023	$ 2,993	$ 9	237,600	(294,433)		29,813	(24,018)
Balance, shares at Dec. 31, 2023	1,305,213	8,578,505
Dividends declared - Series B Convertible Preferred Stock	$ 239			(239)
Dividends declared - Series B Convertible Preferred Stock, shares	79,936
Issue common stock - PAVM ATM Facility			977				977
Issue common stock - PAVM ATM Facility, shares		627,302
Vest - restricted stock awards
Vest - restricted stock awards, shares		135,080
Conversions - Senior Secured Convertible Note		$ 2	2,019				2,021
Conversions - Senior Secured Convertible Note, shares		1,084,366
Conversions - subsidiary common stock - Senior Secured Convertible Note						3,801	3,801
Impact of subsidiary equity transactions			4,414			(4,414)
Issuance - vendor service agreement			200			401	601
Issuance - vendor service agreement, shares		200,809
Stock-based compensation - PAVmed Inc.			2,228				2,228
Transfer of intellectual property to Lucid Diagnostics Inc			350				350
Deconsolidation of subsidiary						(56,339)	(56,339)
Net Loss				38,360		(11,075)	27,285
Exercise - stock options of subsidiary						4	4
Purchase - Employee Stock Purchase Plan			62				62
Purchase - Employee Stock Purchase Plan, shares		34,332
Purchase - subsidiary common stock - Employee Stock Purchase Plan						353	353
Issuance - subsidiary preferred stock (Series A-1)						5,670	5,670
Exchange - subsidiary preferred stock (Series A and Series A-1)						(24,294)	(24,294)
Issuance through exchange - subsidiary preferred stock (Series B and Series B-1)						31,790	31,790
Issuance through sale - subsidiary preferred stock (Series B and Series B-1)						24,129	24,129
Subsidiary deemed dividends on preferred stock attributable to noncontrolling interests						(7,496)	(7,496)
Stock-based compensation - subsidiaries			350			3,139	3,489
Balance at Sep. 30, 2024	$ 3,232	$ 11	248,200	(256,312)		(4,518)	(9,387)
Balance, shares at Sep. 30, 2024	1,385,149	10,660,394
Balance at Jun. 30, 2024	$ 3,151	$ 10	243,524	(320,630)		55,303	(18,642)
Balance, shares at Jun. 30, 2024	1,357,976	9,554,381
Dividends declared - Series B Convertible Preferred Stock	$ 81			(81)
Dividends declared - Series B Convertible Preferred Stock, shares	27,173
Issue common stock - PAVM ATM Facility			284				284
Issue common stock - PAVM ATM Facility, shares		294,003
Vest - restricted stock awards
Vest - restricted stock awards, shares		131,016
Conversions - Senior Secured Convertible Note		$ 1	907				908
Conversions - Senior Secured Convertible Note, shares		509,942
Conversions - subsidiary common stock - Senior Secured Convertible Note						1,260	1,260
Impact of subsidiary equity transactions			2,245			(2,245)
Issuance - vendor service agreement			150				150
Issuance - vendor service agreement, shares		171,052
Stock-based compensation - PAVmed Inc.			696				696
Stock-based compensation - subsidiary			44			1,191	1,235
Transfer of intellectual property to Lucid Diagnostics Inc			350				350
Deconsolidation of subsidiary						(56,339)	(56,339)
Net Loss				64,399		(3,688)	60,711
Balance at Sep. 30, 2024	$ 3,232	$ 11	$ 248,200	$ (256,312)		$ (4,518)	$ (9,387)
Balance, shares at Sep. 30, 2024	1,385,149	10,660,394

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Cash flows from operating activities
Net income (loss) - before noncontrolling interest (“NCI”)	$ 60,711	$ (21,750)	$ 27,285	$ (61,855)
Adjustments to reconcile net income (loss) - before NCI to net cash used in operating activities
Depreciation and amortization expense			1,129	2,207
Stock-based compensation	1,931	2,245	5,716	9,171
Gain on sale of intellectual property				(1,000)
Gain on deconsolidation of subsidiary	(72,287)		(72,287)
Change in fair value - equity method investment	(407)		(407)
APA-RDx: Issue common stock of subsidiary - termination payment				713
Amortization of common stock payment for vendor service agreement			448	625
Change in fair value - Senior Secured Convertible Notes	(240)	4,392	2,488	5,772
Loss on issue - Senior Secured Convertible Note				1,111
Debt extinguishment loss - Senior Secured Convertible Note	1,403	1,764	2,535	3,032
Change in fair value - derivative liability				291
Non-cash lease expense			8	304
Changes in operating assets and liabilities:
Accounts receivable			45	(18)
Prepaid expenses, deposits and current and other assets			579	(1,757)
Accounts payable			(249)	(538)
Accrued expenses and other current liabilities			(938)	1,780
Net cash flows used in operating activities			(33,648)	(40,162)
Cash flows from investing activities
Purchase of equipment			(51)	(59)
Decrease in cash due to deconsolidation of subsidiary			(16,479)
Proceeds from sale of intellectual property to Lucid Diagnostics Inc.			350
Proceeds from sale of intellectual property				1,000
Net cash flows provided by (used in) investing activities			(16,180)	941
Cash flows from financing activities
Proceeds – issue of preferred stock - subsidiary			29,798	13,625
Proceeds – issue of Senior Secured Convertible Note				10,000
Payment – Senior Secured Convertible Note – acceleration floor payments			(531)
Proceeds – issue of common stock - At-The-Market Facility			1,268	1,166
Proceeds – subsidiary common stock - Committed Equity Facility and At-The-Market Facility				284
Proceeds – issue common stock – Employee Stock Purchase Plan			62	259
Proceeds – subsidiary common stock – Employee Stock Purchase Plan			353	551
Proceeds – exercise of stock options issued under equity plan of subsidiary			4
Net cash flows provided by financing activities			30,954	25,885
Net increase (decrease) in cash			(18,874)	(13,336)
Cash, beginning of period			19,639	39,744
Cash, end of period	$ 765	$ 26,408	$ 765	$ 26,408

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Pay vs Performance Disclosure [Table]
Net Income (Loss)	$ 64,399	$ (17,671)	$ 38,360	$ (50,139)

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Sep. 30, 2024
Insider Trading Arrangements [Line Items]
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

The Company

The Company	9 Months Ended
	Sep. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
The Company	Note 1 — The Company Description of the Business PAVmed is structured to be a multi-product life sciences company organized to advance a pipeline of innovative healthcare technologies. Led by a team of highly skilled personnel with a track record of bringing innovative products to market, PAVmed is focused on innovating, developing, acquiring, and commercializing novel products that target unmet medical needs with large addressable market opportunities. Leveraging our corporate structure—a parent company that will establish distinct subsidiaries for each financed asset—we have the flexibility to raise capital at the PAVmed level to fund product development, or to structure financing directly into each subsidiary in a manner tailored to the applicable product, the latter of which is our current strategy given prevailing market conditions. Our current focus is multi-fold. We continue to pursue commercial expansion and execution of EsoGuard, which is the flagship product of our subsidiary, Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”). In addition, through a separate majority-owned subsidiary, Veris Health (“Veris”), we are focused in the immediate term on entering into strategic partnership opportunities with leading academic oncology systems to expand access to the Veris Platform, while concurrently developing an implantable physiological monitor, designed to be implanted alongside a chemotherapy port, which will interface with the Veris Platform. In terms of other existing products and technologies, we have adopted an incubator-type platform where we are looking to obtain financing on a product-by-product basis as necessary to advance each asset to a meaningful inflection point along its path to commercialization. Finally, as resources permit, we will continue to explore external innovations that fulfill our project selection criteria without limiting ourselves to any target sector, specialty or condition.

Liquidity and Going Concern

Liquidity and Going Concern	9 Months Ended
	Sep. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Liquidity and Going Concern	Note 2 — Liquidity and Going Concern The Company’s management is required to assess the Company’s ability to continue as a going concern for the one year period following the date of the financial statements being issued. In each reporting period, including interim periods, an entity is required to assess conditions known and reasonably knowable as of the financial statement issuance date to determine whether it is probable an entity will not meet its financial obligations within one year from the financial statement issuance date. Substantial doubt about an entity’s ability to continue as a going concern exists when conditions and events, considered in the aggregate, indicate it is probable the entity will be unable to meet its financial obligations as they become due within one year after the date the financial statements are issued. The Company has financed its operations principally through public and private issuances of its common stock, preferred stock, common stock purchase warrants, and debt. The Company is subject to all of the risks and uncertainties typically faced by medical device and diagnostic companies that devote substantially all of their efforts to the commercialization of their initial product and services and ongoing research and development activities and conducting clinical trials. The Company generated $ 1.0 3.0 The Company incurred a net income attributable to PAVmed Inc. common stockholders of approximately $ 30.6 33.6 35.4 32.1 0.8 The Company’s ability to continue operations 12 months beyond the issuance of the financial statements, will depend upon its ability to control its operating costs within the limits of the amounts collected from its management service contracts with its non-consolidated subsidiaries, to substantially increase its revenues from the Veris Cancer Care platform, and to raise additional capital through various potential sources including equity or debt financings or refinancing or restructuring existing debt obligations. These factors raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date the accompanying unaudited condensed consolidated financial statements are issued.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2024
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 3 — Summary of Significant Accounting Policies Significant Accounting Policies The Company’s significant accounting policies are as disclosed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023 as filed with the SEC on March 25, 2024, except as otherwise noted herein below. Basis of Presentation The accompanying unaudited condensed consolidated financial statements of PAVmed and those of its wholly owned subsidiaries and variable interest entities have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”), and applicable rules and regulations of the United States Securities and Exchange Commission (“SEC”). All intercompany transactions and balances have been eliminated in consolidation. The Company has a controlling financial interest in Veris Health Inc., with the corresponding noncontrolling interest included as a separate component of consolidated stockholders’ equity (deficit), including the recognition in the unaudited condensed consolidated statement of operations of a net loss attributable to the noncontrolling interest based on the respective minority-interest equity ownership of each subsidiary. As of September 10, 2024, PAVmed ceased to have a controlling financial interest in Lucid Diagnostics and therefore PAVmed’s consolidated results of operations include Lucid Diagnostics’ results of operations only through that date. The deconsolidation of Lucid Diagnostics has resulted in a gain recognized in PAVmed’s statement of operations for the periods ended September 30, 2024. Moving forward, PAVmed will account for its investment in Lucid Diagnostics using the equity method and the fair value option. See below and Note 4, Equity Method Investment Noncontrolling Interest As permitted under SEC rules, certain footnotes or other financial information normally required by U.S. GAAP have been condensed or omitted. The balance sheet as of December 31, 2023 has been derived from audited consolidated financial statements at such date. The accompanying unaudited condensed consolidated financial statements have been prepared on the same basis as the Company’s annual consolidated financial statements, and in the opinion of management, include all adjustments, consisting only of routine recurring adjustments, necessary for a fair statement of the Company’s unaudited condensed consolidated financial information. The unaudited condensed consolidated results of operations for the three and nine months ended September 30, 2024 are not necessarily indicative of the consolidated results to be expected for the year ending December 31, 2024 or for any other interim period or for any other future periods. The accompanying unaudited condensed consolidated financial statements and related unaudited condensed consolidated financial information should be read in conjunction with the Company’s audited consolidated financial statements and related notes thereto as of and for the year ended December 31, 2023 included in the Company’s Annual Report on Form 10-K as filed with the SEC on March 25, 2024. All amounts in the accompanying unaudited condensed consolidated financial statements and the notes thereto are presented in thousands of dollars, if not otherwise noted as being presented in millions of dollars, except for shares and per share amounts. Cash The Company maintains its cash at a major financial institution with high credit quality. At times, the balance of its cash deposits may exceed federally insured limits. The Company has not experienced losses on deposits with commercial banks and financial institutions which exceed federally insured limits. Included in the Company’s cash as of September 30, 2024 and December 31, 2023 is $ 299 Use of Estimates In preparing the unaudited condensed consolidated financial statements in conformity with U.S. GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and the determination of corresponding carrying value reserve, if any, and liabilities and the disclosure of contingent losses, as of the date of the unaudited condensed consolidated financial statements, as well as the reported amounts of revenue and expenses during the reporting period. Significant estimates in these unaudited condensed consolidated financial statements include those related to the estimated fair value of debt obligations, stock-based equity awards, intangible assets and common stock purchase warrants. Other significant estimates include the estimated incremental borrowing rate, the provision or benefit for income taxes and the corresponding valuation allowance on deferred tax assets. Additionally, management’s assessment of the Company’s ability to continue as a going concern involves the estimation of the amount and timing of future cash inflows and outflows. On an ongoing basis, the Company evaluates its estimates and assumptions. The Company bases its estimates on historical experience and on various other assumptions believed to be reasonable. Due to inherent uncertainty involved in making estimates, actual results reported in future periods may be affected by changes in these estimates. Note 3 — Summary of Significant Accounting Policies Revenue Recognition Revenues are recognized when the satisfaction of the performance obligation occurs, in an amount that reflects the consideration the Company expects to collect in exchange for those services. The Company’s revenue was primarily generated by Lucid’s laboratory testing services utilizing its EsoGuard Esophageal DNA tests. The services were completed upon release of a patient’s test result to the ordering healthcare provider. Revenue recognized is inclusive of both variable consideration in connection with an individual patient’s third-party insurance coverage policy and fixed consideration in connection with a contracted services arrangement with an unrelated third party legal entity. To determine revenue recognition for the arrangements that the Company determines are within the scope of ASC 606, Revenue from Contracts with Customers, the Company performs the following five steps: (1) identify the contract(s) with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract and (5) recognize revenue when (or as) the entity satisfies a performance obligation. The key aspects considered by the Company include the following: Contracts Performance obligations Transaction price If the consideration derived from the contracts is deemed to be variable, the Company estimates the amount of consideration to which it will be entitled in exchange for the promised goods or services. The Company limits the amount of variable consideration included in the transaction price to the unconstrained portion of such consideration. In other words, the Company recognizes revenue up to the amount of variable consideration that is not subject to a significant reversal until additional information is obtained or the uncertainty associated with the additional payments or refunds is subsequently resolved. When the Company does not have significant historical experience or that experience has limited predictive value, the constraint over estimates of variable consideration may result in no revenue being recognized upon delivery of patient EsoGuard test results to the ordering healthcare provider. As such, the Company recognizes revenue up to the amount of variable consideration not subject to a significant reversal until additional information is obtained or the uncertainty associated with additional payments or refunds, if any, is subsequently resolved. Differences between original estimates and subsequent revisions, including final settlements, represent changes in estimated expected variable consideration, with the change in estimate recognized in the period of such revised estimate. With respect to a contracted service arrangement, the fixed consideration revenue is recognized on an as-billed basis upon delivery of the laboratory test report with realization of such fixed consideration deemed probable based upon actual historical experience. Allocate transaction price Practical Expedients Note 3 — Summary of Significant Accounting Policies Equity Method Investments Businesses that are not consolidated, but over which PAVmed exercises significant influence, are accounted for under the equity method of accounting. The determination as to whether or not PAVmed exercises significant influence with respect to a company depends on an evaluation of several factors, including, among others, representation on the company’s board of directors and equity ownership level, which is generally between a 20 50 Fair Value Option (“FVO”) Election Under a Securities Purchase Agreement dated March 31, 2022, the Company issued a Senior Secured Convertible Note dated April 4, 2022, referred to herein as the “April 2022 Senior Convertible Note”, and a Senior Secured Convertible Note dated September 8, 2022, referred to herein as the “September 2022 Senior Convertible Note”, which are accounted under the “fair value option election” as discussed below. Under a Securities Purchase Agreement dated March 13, 2023, Lucid Diagnostics issued a Senior Secured Convertible Note dated March 21, 2023, referred to herein as the “Lucid March 2023 Senior Convertible Note”, which is accounted under the “fair value option election”, through September 10, 2024, the date of Lucid’s deconsolidation from PAVmed’s results of operations, as discussed below. Under Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 815, Derivative and Hedging Alternatively, FASB ASC Topic 825, Financial Instruments See Note 10, Financial Instruments Fair Value Measurements Debt From and after September 10, 2024, the date of Lucid’s deconsolidation from PAVmed’s results of operation, the Company’s investment in Lucid is treated as an equity method investment accounted for using the fair value option. Shares of Lucid Diagnostics common stock have a readily determinable fair value classified as Level 1, in which the fair value is determined based upon quoted market prices in an active market. Recent Accounting Standards Updates Not Yet Adopted In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740)—Improvements to Income Tax Disclosures (“ASU 2023-09”), which is intended to enhance the transparency and decision usefulness of income tax disclosures. The amendments in ASU 2023-09 provide for enhanced income tax information primarily through changes to the rate reconciliation and income taxes paid information. ASU 2023-09 is effective for the Company prospectively to all annual periods beginning after December 15, 2024. Early adoption is permitted. The Company does not expect the standard to have a significant impact on its unaudited condensed consolidated financial statements. In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280)—Improvements to Reportable Segment Disclosures (“ASU 2023-07”), which require public companies disclose significant segment expenses and other segment items on an annual and interim basis and to provide in interim periods all disclosures about a reportable segment’s profit or loss and assets that are currently required annually. The guidance is effective for public entities for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The guidance is applied retrospectively to all periods presented in the financial statements, unless it is impracticable. The Company is currently evaluating the impact this update will have on its unaudited condensed consolidated financial statements and disclosures, however the Company does not expect the standard to have a significant impact. Note 3 — Summary of Significant Accounting Policies In October 2023, the FASB issued ASU No. 2023-06, Disclosure Improvements: Codification Amendments in Response to the SEC’s Disclosure Update and Simplification Initiative. This update modifies the disclosure or presentation requirements of a variety of topics in the Accounting Standards Codification to conform with certain SEC amendments in Release No. 33-10532, Disclosure Update and Simplification. The amendments in this update should be applied prospectively, and the effective date for each amendment will be the date on which the SEC’s removal of that related disclosure from Regulation S-X or S-K becomes effective. However, if the SEC has not removed the related disclosure from its regulations by June 30, 2027, the amendments will be removed from the Codification and not become effective. Early adoption is prohibited. The Company is currently evaluating the impact this update will have on its unaudited condensed consolidated financial statements and disclosures.

Equity Method Investment

Equity Method Investment	9 Months Ended
	Sep. 30, 2024
Equity Method Investments and Joint Ventures [Abstract]
Equity Method Investment	Note 4 — Equity Method Investment On September 10, 2024, following preferred equity transactions completed by Lucid earlier in 2024 and the termination of voting proxies entered into between PAVmed and certain shareholders of Lucid, PAVmed’s voting interest in the Company was reduced to less than 50.0 Schedule of Deconsolidation of Net Assets Assets: Current assets: Cash $ 16,479 Prepaid expenses, deposits, and other current assets 3,474 Total current assets 19,953 Fixed assets, net 964 Operating lease right-of-use assets 2,871 Intangible assets, net 877 Other assets 379 Total assets 25,044 Liabilities: Current liabilities: Accounts payable 1,069 Accrued expenses and other current liabilities 1,674 Operating lease liabilities, current portion 865 Senior Secured Convertible Notes - at fair value 10,268 Total current liabilities 13,876 Operating lease liabilities, less current portion 2,011 Total liabilities 15,887 Net Assets of Lucid Diagnostics at September 10, 2024 $ 9,157 Upon deconsolidation, the Company owned 31,302,444 25.1 72.3 Schedule of Gain on Deconsolidation Investment in former Consolidated Subsidiary (Fair Value of Lucid common stock) $ 25,105 Add: Noncontrolling interest - Lucid 56,339 Less: Net Assets of Former Consolidated Subsidiary - Lucid (9,157 ) Gain on Deconsolidation of Lucid $ 72,287 After the Company’s deconsolidation of Lucid, the Company accounts for its investment in Lucid as an equity method investment with the election of the fair value option. Due to the Company’s continuing involvement and significant influence over operating and financial policies, Lucid is considered a related party of the Company. Note 4 — Equity Method Investment - The following unaudited summarized financial information related to Lucid accounted for under the equity method of accounting as of September 30, 2024. This aggregate information has been compiled from the financial statements of those business. Schedule of Aggregate Information From the Financial Statements September 30, 2024 Cash $ 14,489 Other current assets 2,335 Non-current assets 5,774 Total assets 22,598 Current liabilities 14,249 Non-current liabilities 2,011 Shareholders’ deficit 6,338 Total liabilities and stockholders’ deficit $ 22,598 Three months ended September 30, 2024 July 1, 2024 - September 10, 2024 September 11, 2024 - September 30, 2024 Total Revenue $ 942 $ 230 $ 1,172 Net income (loss) $ (9,039 ) $ (3,332 ) $ (12,371 ) Nine months ended September 30, 2024 January 1, 2024 - September 10, 2024 September 11, 2024 - September 30, 2024 Total Revenue $ 2,919 $ 230 $ 3,149 Net income (loss) $ (38,152 ) $ (3,332 ) $ (41,484 ) *Lucid was consolidated and included in PAVmed’s consolidated results for the period of January 1, 2024 through September 10, 2024. The amounts from September 11, 2024 through September 30, 2024 were not included in PAVmed’s consolidated results. At September 10, 2024 and September 30, 2024, the fair value of the Company’s investment in Lucid was $ 25.1 25.5 0.4 0.802 0.815 40 Lucid - Management Services Agreement Lucid’s daily operations are also managed in part by personnel employed by the Company, for which the Company records management fee income, referred to as the “MSA Fee”, according to the provisions of a Management Services Agreement (“MSA”) with Lucid. The MSA does not have a termination date, but may be terminated by Lucid. The MSA Fee is charged on a monthly basis and is subject-to periodic adjustment corresponding with changes in the services provided by the Company’s personnel to Lucid, with any such change in the MSA Fee being subject to approval of the boards of directors of each of the Company and Lucid. The respective companies’ boards of directors approved an amendment to the MSA to increase the MSA Fee to $ 833 833 1,050 700 Transfer of Intellectual Property to Lucid On September 27, 2024, the Company entered into an Assignment of Patent Rights with PAVmed, pursuant to which PAVmed assigned certain patent rights to the Company related to the EsoCheck device. In consideration of the assignment the Company agreed to pay PAVmed a $ 350

Revenue from Contracts with Cus

Revenue from Contracts with Customers	9 Months Ended
	Sep. 30, 2024
Revenue from Contract with Customer [Abstract]
Revenue from Contracts with Customers	Note 5 — Revenue from Contracts with Customers Revenue Recognized In the three and nine month periods ended September 30, 2024, the Company recognized total revenue of $ 996 2,985 791 1,403 Cost of Revenue The cost of revenues principally includes the costs related to the Company’s laboratory operations (excluding estimated costs associated with research activities), the costs related to the EsoCheck cell collection device, cell sample mailing kits and license royalties. In the three and nine month periods ended September 30, 2024, the cost of revenue was $ 1,381 4,792 1,779 4,809

Prepaid Expenses, Deposits, and

Prepaid Expenses, Deposits, and Other Current Assets	9 Months Ended
	Sep. 30, 2024
Prepaid Expenses Deposits And Other Current Assets
Prepaid Expenses, Deposits, and Other Current Assets	Note 6 — Prepaid Expenses, Deposits, and Other Current Assets Prepaid expenses and other current assets consisted of the following as of: Schedule of Prepaid Expenses and Other Current Assets September 30, 2024 December 31, 2023 Advanced payments to service providers and suppliers $ 181 $ 739 Prepaid insurance 420 848 Deposits 480 2,672 Veris Box supplies 262 261 Total prepaid expenses, deposits and other current assets $ 1,343 $ 4,520

Leases

Leases	9 Months Ended
	Sep. 30, 2024
Leases
Leases	Note 7 — Leases The Company’s future lease payments as of September 30, 2024, which are presented as operating lease liabilities, current portion and operating lease liabilities, less current portion on the Company’s unaudited condensed consolidated balance sheets are as follows: Schedule of Future Minimum Lease Payments for Operating Leases 2024 (remainder of year) $ 174 2025 708 2026 724 2027 594 2028 471 Thereafter 848 Total lease payments $ 3,519 Less: imputed interest (640 ) Present value of lease liabilities $ 2,879 Supplemental disclosure of cash flow information related to the Company’s cash and non-cash activities with its leases are as follows: Schedule of Supplemental Balance Sheet Information Related to Cash and Non-cash Activities with Leases 2024 2023 Nine Months Ended September 30, 2024 2023 Cash paid for amounts included in the measurement of lease liabilities Operating cash flows from operating leases $ 1,407 $ 1,080 Non-cash investing and financing activities Right-of-use assets obtained in exchange for new operating lease liabilities $ — $ 2,728 Weighted-average remaining lease term - operating leases (in years) 5.25 6.68 Weighted-average discount rate - operating leases 7.875 % 7.875 % As of September 30, 2024 and December 31, 2023, the Company’s right-of-use assets from operating leases were $ 2,618 4,267 2,879 4,525 499 1,565 2,380 2,960 Equity Method Investment

Intangible Assets, net

Intangible Assets, net	9 Months Ended
	Sep. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets, net	Note 8 — Intangible Assets, net Intangible assets, less accumulated amortization, consisted of the following as of: Schedule of Intangible Assets, Less Accumulated Amortization Estimated Useful Life September 30, 2024 December 31, 2023 Defensive asset 60 $ — $ 2,105 Laboratory licenses and certifications and laboratory information management software 24 — 3,200 Other 1 year 70 70 Total Intangible assets 70 5,375 Less Accumulated Amortization (70 ) (3,951 ) Intangible Assets, net $ — $ 1,424 Amortization expense of the intangible assets discussed above was $ 82 505 559 1,516 0 no Equity Method Investment

Commitment and Contingencies

Commitment and Contingencies	9 Months Ended
	Sep. 30, 2024
Commitments and Contingencies Disclosure [Abstract]
Commitment and Contingencies	Note 9 — Commitment and Contingencies Other Matters In the ordinary course of PAVmed business, particularly as it begins commercialization of its products, the Company may be subject to certain other legal actions and claims, including product liability, consumer, commercial, tax and governmental matters, which may arise from time to time. The Company is not aware of any such pending legal or other proceedings that are reasonably likely to have a material impact on the Company. Notwithstanding, legal proceedings are subject-to inherent uncertainties, and an unfavorable outcome could include monetary damages, and excessive verdicts can result from litigation, and as such, could result in a material adverse impact on the Company’s business, financial position, results of operations, and /or cash flows. Additionally, although the Company has specific insurance for certain potential risks, the Company may in the future incur judgments or enter into settlements of claims which may have a material adverse impact on the Company’s business, financial position, results of operations, and /or cash flows.

Financial Instruments Fair Valu

Financial Instruments Fair Value Measurements	9 Months Ended
	Sep. 30, 2024
Fair Value Disclosures [Abstract]
Financial Instruments Fair Value Measurements	Note 10 — Financial Instruments Fair Value Measurements Recurring Fair Value Measurements The fair value hierarchy table for the periods indicated is as follows: Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis Fair Value Measurement on a Recurring Basis at Reporting Date Using 1 Level-1 Inputs Level-2 Inputs Level-3 Inputs Total September 30, 2024 Assets: Investment in Lucid Diagnostics, Inc common stock $ 25,511 $ — $ — $ 25,511 Total assets at fair value $ 25,511 $ — $ — $ 25,511 Liabilities: Senior Secured Convertible Note - April 2022 — — 19,850 19,850 Senior Secured Convertible Note - September 2022 — — 12,200 12,200 Total liabilities at fair value $ — $ — $ 32,050 $ 32,050 Level-1 Inputs Level-2 Inputs Level-3 Inputs Total December 31, 2023 Liabilities: Senior Secured Convertible Note - April 2022 $ — $ — $ 19,000 $ 19,000 Senior Secured Convertible Note - September 2022 — — 11,250 11,250 Lucid Senior Secured Convertible Note - March 2023 — — 13,950 13,950 Total liabilities at fair value $ — $ — $ 44,200 $ 44,200 1 There were no transfers between the respective Levels during the nine months ended September 30, 2024. As discussed in Note 11, Debt 27.5 11.25 As discussed in Note 11, Debt, 11.1 The estimated fair value of the financial instruments classified within the Level 3 category was determined using both observable inputs and unobservable inputs. Unrealized gains and losses associated with liabilities within the Level 3 category include changes in fair value attributable to both observable (e.g., changes in market interest rates) and unobservable (e.g., changes in unobservable long- dated volatilities) inputs. Note 10 — Financial Instruments Fair Value Measurements The estimated fair value of the April 2022 Senior Convertible Note and the September 2022 Senior Convertible Note as of September 30, 2024 and the estimated fair value of the April 2022 Senior Convertible Note, the September 2022 Senior Convertible Note and the Lucid March 2023 Senior Convertible Note as of December 31, 2023, were computed using a Monte Carlo simulation of the present value of its cash flows using a synthetic credit rating analysis and a required rate-of-return, using the following assumptions: Schedule of Fair Value Assumption Used April 2022 Senior September 2022 Senior Fair Value $ 19,850 $ 12,200 Face value principal payable $ 17,602 $ 7,627 Required rate of return 9.000 % 8.800 % Conversion Price $ 75.00 $ 75.00 Value of common stock $ 1.23 $ 1.23 Expected term (years) 0.51 0.94 Volatility 160.00 % 160.00 % Risk free rate 4.28 % 3.95 % Dividend yield — % — % April 2022 Senior September 2022 Lucid March 2023 Fair Value $ 19,000 $ 11,250 $ 13,950 Face value principal payable $ 17,602 $ 9,062 $ 11,019 Required rate of return 10.00 10.50 % 10.00 10.20 % 10.00 % Conversion Price $ 75.00 $ 75.00 $ 5.00 Value of common stock $ 4.12 $ 4.12 $ 1.41 Expected term (years) 0.26 1.26 0.69 1.69 1.22 Volatility 85.00 % 85.00 % 60.00 % Risk free rate 4.54 5.25 % 4.31 4.96 % 4.56 % Dividend yield — % — % — % The estimated fair values recognized utilized PAVmed’s and Lucid’s common stock prices, along with certain Level 3 inputs (as presented in the respective tables above), in the development of Monte Carlo simulation models, discounted cash flow analyses, and /or Black-Scholes valuation models. The estimated fair values are subjective and are affected by changes in inputs to the valuation models and analyses, including the respective common stock prices, as compared to the floor price on conversions, the dividend yields, the risk-free rates based on U.S. Treasury security yields, and certain other Level-3 inputs including, assumptions regarding the estimated volatility in the value of the respective common stock prices. Changes in these assumptions can materially affect the recognized estimated fair values.

Debt

Debt	9 Months Ended
	Sep. 30, 2024
Debt Disclosure [Abstract]
Debt	Note 11 — Debt The fair value and face value principal outstanding of the Senior Convertible Notes as of the dates indicated are as follows: Summary of Outstanding Debt Contractual Maturity Date Stated Interest Rate Conversion Face Value Fair Value April 2022 Senior Convertible Note April 4, 2025 7.875 % $ 75.00 $ 17,602 $ 19,850 September 2022 Senior Convertible Note September 8, 2025 7.875 % $ 75.00 7,627 12,200 Balance as of September 30, 2024 $ 25,229 $ 32,050 Contractual Maturity Date Stated Interest Rate Conversion Price per Share Face Value Principal Outstanding Fair Value April 2022 Senior Convertible Note April 4, 2025 7.875 % $ 75.00 $ 17,602 $ 19,000 September 2022 Senior Convertible Note September 8, 2025 7.875 % $ 75.00 9,062 11,250 Lucid March 2023 Senior Convertible Note March 21, 2025 7.875 % $ 5.00 11,019 13,950 Balance as of December 31, 2023 $ 37,683 $ 44,200 The changes in the fair value of debt during the three and nine month periods ended September 30, 2024 is as follows: Schedule of Changes in Fair Value of Debt April 2022 Senior Convertible Note September 2022 Senior Convertible Note Lucid March 2023 Senior Convertible Note Sum of Balance Sheet Fair Value Components Other Income (expense) Fair Value - June 30, 2024 $ 19,200 $ 13,600 $ 11,200 $ 44,000 $ — Face value principal – issue date Fair value adjustment – issue date Installment repayments – common stock — (455 ) (797 ) (1,252 ) — Non-installment payments – common stock — (55 ) (135 ) (190 ) — Deconsolidation of Lucid Diagnostics — — (10,268 ) (10,268 ) — Change in fair value 650 (890 ) — (240 ) 240 Fair Value at September 30, 2024 $ 19,850 $ 12,200 $ — $ 32,050 - Other Income (Expense) - Change in fair value – three month period ended September 30, 2024 $ 240 April 2022 Senior Convertible Note September 2022 Senior Convertible Note Lucid March 2023 Senior Convertible Note Sum of Balance Sheet Fair Value Components Other Income (expense) Fair Value - December 31, 2023 $ 19,000 $ 11,250 $ 13,950 $ 44,200 $ — Installment repayments – common stock — (1,435 ) (2,005 ) (3,440 ) — Non-installment payments – common stock — (143 ) (787 ) (930 ) — Deconsolidation of Lucid Diagnostics — — (10,268 ) (10,268 ) — Change in fair value 850 2,528 (890 ) 2,488 (2,488 ) Fair Value at September 30, 2024 $ 19,850 $ 12,200 $ — $ 32,050 - Other Income (Expense) - Change in fair value – nine month period ended September 30, 2024 $ (2,488 ) Note 11 — Debt The changes in the fair value of debt during the three and nine month periods ended September 30, 2023 is as follows: April 2022 Senior Convertible Note September 2022 Senior Convertible Note Lucid March 2023 Senior Convertible Note Sum of Balance Sheet Fair Value Components Other Income (expense) Fair Value - June 30, 2023 $ 19,530 $ 11,850 $ 11,610 $ 42,990 $ — Installment repayments – common stock (952 ) (1,207 ) (92 ) (2,251 ) — Non-installment payments – common stock (41 ) (51 ) (49 ) (141 ) — Change in fair value 863 508 3,021 4,392 (4,392 ) Fair Value at September 30, 2023 $ 19,400 $ 11,100 $ 14,490 $ 44,990 - Other Income (Expense) - Change in fair value – three month period ended September 30, 2023 $ (4,392 ) April 2022 Senior Convertible Note September 2022 Senior Convertible Note Lucid March 2023 Senior Convertible Note Sum of Balance Sheet Fair Value Components Other Income (expense) Fair Value - December 31, 2022 $ 22,000 $ 11,650 $ — $ 33,650 $ — Fair Value - Beginning of Period $ 22,000 $ 11,650 $ — $ 33,650 $ — Face value principal – issue date — — 11,111 11,111 — Fair value adjustment – issue date — — 789 789 (789 ) Installment repayments – common stock (3,895 ) (1,207 ) (92 ) (5,194 ) — Non-installment payments – common stock (249 ) (51 ) (49 ) (349 ) — Change in fair value 1,544 708 2,731 4,983 (4,983 ) Fair Value at September 30, 2023 $ 19,400 $ 11,100 $ 14,490 $ 44,990 - Fair Value - Ending of Period $ 19,400 $ 11,100 $ 14,490 $ 44,990 - Other Income (Expense) - Change in fair value – nine month period ended September 30, 2023 $ (5,772 ) PAVmed - Senior Secured Convertible Notes The Company entered into a Securities Purchase Agreement (“SPA”) dated March 31, 2022, with an accredited institutional investor (“Investor”, “Lender”, and /or “Holder”), wherein, the Company agreed to sell, and the Investor agreed to purchase an aggregate of $ 50.0 27.5 22.5 Under the SPA, the Company issued a Senior Secured Convertible Note dated April 4, 2022, referred to herein as the “April 2022 Senior Convertible Note”, with such note having a $ 27.5 7.875 75.00 April 4, 2024 maturity date the investor agreed to extend by one year, to April 4, 2025 Under the same SPA, the Company issued an additional Senior Secured Convertible Note dated September 8, 2022, referred to herein as the “September 2022 Senior Convertible Note”, with such note having a $ 11.25 7.875 75.00 September 6, 2024 maturity date the investor agreed to extend by one year, to September 8, 2025. Note 11 — Debt The Company agreed to reduce temporarily, and the Investor consented to reducing temporarily, the contractual conversion price under the April 2022 Senior Convertible Note and the September 2022 Senior Convertible Note to equal to 82.5 0.40 1 The Company is subject to financial covenants requiring: (i) a minimum of $8.0 million of available cash at all times; (ii) the ratio of (a) the outstanding principal amount of the total senior convertible notes outstanding, accrued and unpaid interest thereon and accrued and unpaid late charges to (b) the Company’s average market capitalization over the prior ten trading days, to not exceed 30% (the “Debt to Market Cap Ratio Test”); and (iii) the Company’s market capitalization to at no time be less than $75 million In consideration of a prior covenant waiver and maturity extension agreed to in March 2024, the Company agreed to pay the holder of the notes $ 2,000 The April 2022 Senior Convertible Note and September 2022 Senior Convertible Note installment payments may be made in shares of PAVmed common stock at a conversion price that is the lower of the contractual conversion price and 82.5 2.70 In the three and nine month periods ended September 30, 2024, approximately $ 455 1,435 55 143 509,942 1,084,366 907 2,002 652 1,059 652 1,050 1,501 Lucid Diagnostics - Senior Secured Convertible Note Following the deconsolidation of Lucid, the Lucid March 2023 Senior Convertible Note is no longer reflected in the Company’s unaudited condensed consolidated balance sheets. See Note 4, Equity Method Investment During the period of January 1, 2024 through September 10, 2024, the date of Lucid’s deconsolidation, approximately $ 2,005 787 4,172,002 3,801 328 1,009 During the three and nine month periods ended September 30, 2024, the Company recognized debt extinguishment losses in total of approximately $ 1,403 2,535 1,764 3,032 See Note 10, Financial Instruments Fair Value Measurements

Stock-Based Compensation

Stock-Based Compensation	9 Months Ended
	Sep. 30, 2024
Retirement Benefits [Abstract]
Stock-Based Compensation	Note 12 — Stock-Based Compensation PAVmed Inc. 2014 Long-Term Incentive Equity Plan The PAVmed Inc. 2014 Long-Term Incentive Equity Plan (the “PAVmed 2014 Equity Plan”) is designed to enable PAVmed to offer employees, officers, directors, and consultants, as defined, an opportunity to acquire shares of common stock of PAVmed. The types of awards that may be granted under the PAVmed 2014 Equity Plan include stock options, stock appreciation rights, restricted stock, and other stock-based awards subject to limitations under applicable law. All awards are subject to approval by the PAVmed compensation committee. A total of 1,835,970 79,321 66,720 432,452 PAVmed Stock Options PAVmed stock options granted under the PAVmed 2014 Equity Plan and stock options granted outside such plan are summarized as follows: Schedule of Summarizes Information About Stock Options Number of Stock Options Weighted Average Exercise Price Remaining Contractual Term (Years) Intrinsic Value (2) Outstanding stock options at December 31, 2023 1,192,458 $ 26.18 7.3 $ — Granted (1) 79,500 $ 2.28 Exercised — $ — Forfeited (38,851 ) $ 13.47 Outstanding stock options at September 30, 2024 (3) 1,233,107 $ 25.04 5.9 $ — Vested and exercisable stock options at September 30, 2024 956,977 $ 30.27 5.1 $ — (1) Stock options granted under the PAVmed 2014 Equity Plan and those granted outside such plan generally vest one-third in one year then ratably over the next eight quarters, and have a ten-year contractual term from date-of-grant. (2) The intrinsic value is computed as the difference between the quoted price of the PAVmed common stock on each of September 30, 2024 and December 31, 2023 and the exercise price of the underlying PAVmed stock options, to the extent such quoted price is greater than the exercise price. (3) The outstanding stock options presented in the table above are inclusive of 60,054 On February 22, 2024, the Company granted 59,500 1.85 390,000 0.7 PAVmed Restricted Stock Awards PAVmed restricted stock awards granted under the PAVmed 2014 Equity Plan and restricted stock awards granted outside such plan are summarized as follows: Schedule of Restricted Stock Award Activity Number of Restricted Stock Awards Weighted Average Grant Date Fair Value Unvested restricted stock awards as of December 31, 2023 70,527 $ 38.77 Granted 390,000 1.85 Vested (135,080 ) 2.00 Forfeited — — Unvested restricted stock awards as of September 30, 2024 325,447 $ 9.79 Note 12 — Stock-Based Compensation Lucid Diagnostics Inc. 2018 Long-Term Incentive Equity Plan The Lucid Diagnostics Inc. 2018 Long-Term Incentive Equity Plan (“Lucid Diagnostics 2018 Equity Plan”) is separate and apart from the PAVmed 2014 Equity Plan discussed above. The Lucid Diagnostics 2018 Equity Plan is designed to enable Lucid Diagnostics to offer employees, officers, directors, and consultants, an opportunity to acquire shares of common stock of Lucid Diagnostics. The types of awards that may be granted under the Lucid Diagnostics 2018 Equity Plan include stock options, stock appreciation rights, restricted stock, and other stock-based awards subject to limitations under applicable law. All awards are subject to approval by the Lucid Diagnostics compensation committee. Please note that following the deconsolidation of Lucid, the Lucid Diagnostics 2018 Long-Term Equity Plan is no longer reflected in the Company’s unaudited condensed consolidated statements of operations. Lucid continues to be responsible for administering its equity plan. See Note 4, Equity Method Investment Lucid Diagnostics Stock Options Lucid Diagnostics stock options granted under the Lucid Diagnostics 2018 Equity Plan and stock options granted outside such plan are summarized as follows: Schedule of Summarizes Information About Stock Options Number of Stock Options Weighted Average Exercise Price Remaining Contractual Term (Years) Intrinsic Value (2) Outstanding stock options at December 31, 2023 5,504,383 $ 2.00 8.5 $ 765 Granted (1) 3,604,000 $ 1.22 Exercised (3,333 ) $ 1.31 Forfeited (417,501 ) $ 1.63 Outstanding stock options at September 10, 2024 (3) 8,687,549 $ 1.69 8.3 $ 191 Vested and exercisable stock options at September 10, 2024 3,084,682 $ 2.25 7.1 $ 191 (1) Stock options granted under the Lucid Diagnostics 2018 Equity Plan and those granted outside such plan generally vest one-third in one year then ratably over the next eight quarters, and have a ten-year contractual term from date-of-grant. (2) The intrinsic value is computed as the difference between the quoted price of the Lucid Diagnostics common stock on each of September 10, 2024 and December 31, 2023 and the exercise price of the underlying Lucid Diagnostics stock options, to the extent such quoted price is greater than the exercise price. (3) The outstanding stock options presented in the table above are inclusive of 523,300 On February 22, 2024, Lucid granted 2,895,000 1.25 Lucid Diagnostics Restricted Stock Awards Lucid Diagnostics restricted stock awards granted under the Lucid Diagnostics 2018 Equity Plan and restricted stock awards granted outside such plan are summarized as follows: Schedule of Restricted Stock Award Activity Number of Restricted Stock Awards Weighted Average Grant Date Fair Value Unvested restricted stock awards as of December 31, 2023 2,337,440 $ 8.99 Granted 1,600,000 1.03 Vested (26,912 ) 4.56 Forfeited (13,088 ) 4.56 Unvested restricted stock awards as of September 10, 2024 3,897,440 $ 5.77 In May 2024, a total of 1,600,000 1.5 Note 12 — Stock-Based Compensation Consolidated Stock-Based Compensation Expense The consolidated stock-based compensation expense recognized by each of PAVmed and (through September 10, 2024, the date of PAVmed’s deconsolidation of Lucid) Lucid Diagnostics for both the PAVmed 2014 Equity Plan and the Lucid Diagnostics 2018 Equity Plan, with respect to stock options and restricted stock awards as discussed above, for the periods indicated, was as follows: Schedule of Stock-Based Compensation Expense 2024 2023 2024 2023 Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 Cost of revenue $ 32 $ 32 $ 112 $ 86 Sales and marketing expenses 292 403 1,082 1,302 General and administrative expenses 1,426 1,499 3,717 6,761 Research and development expenses 181 311 805 1,022 Total stock-based compensation expense $ 1,931 $ 2,245 $ 5,716 $ 9,171 Stock-Based Compensation Expense Recognized by Lucid Diagnostics As noted, the consolidated stock-based compensation expense presented above is inclusive of stock-based compensation expense recognized by Lucid Diagnostics (through September 10, 2024, the date of PAVmed’s deconsolidation of Lucid) inclusive of each of: stock options granted under the PAVmed 2014 Equity Plan to the three physician inventors of the intellectual property underlying the Amended CWRU License Agreement; and stock options and restricted stock awards granted to employees of PAVmed and non-employee consultants under the Lucid Diagnostics 2018 Equity Plan. The stock-based compensation expense recognized by Lucid Diagnostics (through September 10, 2024, the date of PAVmed’s deconsolidation of Lucid) for both the PAVmed 2014 Equity Plan and the Lucid Diagnostics 2018 Equity Plan, with respect to stock options and restricted stock awards as discussed above, for the periods indicated, was as follows: Schedule of Stock-Based Compensation Expense Recognized by Lucid Diagnostics 2024 2023 2024 2023 Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 Lucid Diagnostics 2018 Equity Plan – cost of revenue $ 24 $ 16 $ 81 $ 44 Lucid Diagnostics 2018 Equity Plan – sales and marketing 252 228 849 697 Lucid Diagnostics 2018 Equity Plan – general and administrative 548 721 1,484 4,069 Lucid Diagnostics 2018 Equity Plan – research and development 98 67 356 204 PAVmed 2014 Equity Plan - cost of revenue 9 10 30 26 PAVmed 2014 Equity Plan - sales and marketing 18 106 136 359 PAVmed 2014 Equity Plan - general and administrative 1 7 5 170 PAVmed 2014 Equity Plan - research and development 5 97 148 290 Total stock-based compensation expense – recognized by Lucid Diagnostics $ 955 $ 1,252 $ 3,089 $ 5,859 Total stock-based compensation expense $ 955 $ 1,252 $ 3,089 $ 5,859 The consolidated unrecognized stock-based compensation expense and weighted average remaining requisite service period with respect to stock options and restricted stock awards issued under the PAVmed 2014 Equity Plan, as discussed above, is as follows: Schedule of Unrecognized Compensation Expense Unrecognized Expense Weighted Average Remaining Service Period (Years) PAVmed 2014 Equity Plan Stock Options $ 1,377 1.5 Restricted Stock Awards $ 397 2.2 Note 12 — Stock-Based Compensation Stock-based compensation expense recognized with respect to stock options granted under the PAVmed 2014 Equity Plan was based on a weighted average estimated fair value of such stock options of $ 1.47 5.25 Schedule of Fair Values of Stock Options Granted Using Black-scholes Valuation Model Assumptions Nine Months Ended September 30, 2024 2023 Expected term of stock options (in years) 5.8 5.7 Expected stock price volatility 90 % 88 % Risk free interest rate 4.3 % 3.7 % Expected dividend yield — % — % Stock-based compensation expense recognized with respect to stock options granted under the Lucid Diagnostics 2018 Equity Plan was based on a weighted average estimated fair value of such stock options of $ 0.79 0.88 Schedule of Fair Values of Stock Options Granted Using Black-scholes Valuation Model Assumptions Nine Months Ended September 30, 2024 2023 Expected term of stock options (in years) 5.7 5.6 Expected stock price volatility 73 % 75 % Risk free interest rate 4.3 % 3.7 % Expected dividend yield — % — % PAVmed Inc. Employee Stock Purchase Plan (“PAVmed ESPP”) A total of 34,332 38,216 62 182 20,267 76 12,590 300,001 139,863 166,667 Effective September 18, 2024, PAVmed’s compensation committee temporarily suspended any participation in the PAVmed ESPP. Accordingly, no shares of common stock of the Company have been purchased under the PAVmed ESPP since March 31, 2024. Lucid Diagnostics Inc. Employee Stock Purchase Plan (“Lucid ESPP”) A total of 511,884 231,987 353 276 276,213 275

Preferred Stock

Preferred Stock	9 Months Ended
	Sep. 30, 2024
Equity [Abstract]
Preferred Stock	Note 13 — Preferred Stock As of September 30, 2024 and December 31, 2023, there were 1,385,149 1,305,213 PAVmed Series B Convertible Preferred Stock Dividends The Series B Convertible Preferred Stock is issued pursuant to the PAVmed Inc. Certificate of Designation of Preferences, Rights, and Limitations of Series B Convertible Preferred Stock (“Series B Convertible Preferred Stock Certificate of Designation”), has a par value of $ 0.001 3.00 The PAVmed Inc. Series B Convertible Preferred Stock dividends are 8.0 3.00 PAVmed Series B Convertible Preferred Stock Dividends Earned The Series B Convertible Preferred Stock dividends earned are included in the calculation of basic and diluted net loss attributable to PAVmed common stockholders for each of the respective corresponding periods presented in the accompanying unaudited condensed consolidated statement of operations, inclusive of $ 83 244 77 226 PAVmed Series B Convertible Preferred Stock Dividends Declared During the nine months ended September 30, 2024, the Company’s board of directors declared an aggregate of approximately $ 239 78 80 81 79,936 26,123 26,640 27,173 During the nine months ended September 30, 2023, the Company’s board of directors declared an aggregate of approximately $ 221 72 74 75 73,842 24,128 24,610 25,104 Subsequent to September 30, 2024, in November 2024, the Company’s board of directors declared a PAVmed Series B Convertible Preferred Stock dividend, earned as of September 30, 2024, of $ 83 27,716 The PAVmed Series B Convertible Preferred Stock dividends are recognized as a dividend payable liability only upon the dividend being declared payable by the Company’s board of directors. Accordingly, the dividends declared payable subsequent to the date of the accompanying unaudited condensed consolidated balance sheet were not recognized as a dividend payable liability as the Company’s board of directors had not declared the dividends payable as of each such date.

Common Stock and Common Stock P

Common Stock and Common Stock Purchase Warrants	9 Months Ended
	Sep. 30, 2024
Equity [Abstract]
Common Stock and Common Stock Purchase Warrants	Note 14 — Common Stock and Common Stock Purchase Warrants Common Stock In February 2023, the Company distributed a proxy statement for a special meeting of shareholders that was held on March 31, 2023 (the “Special Meeting”), at which the Company sought approval of an amendment to the Company’s Certificate of Incorporation, to effect, (i) a reverse split of the Company’s outstanding shares of common stock at a specific ratio, ranging from 1-for-5 1-for-15 250,000,000 50,000,000 1-for-15 every 15 shares of the Company’s common stock that were issued and outstanding were automatically combined into one issued and outstanding share, without any change in par value of such shares. On March 7, 2024, the Company received a notice from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) stating that, for the prior 30 consecutive business days (through March 6, 2024), the market value of the Company’s listed securities had been below the minimum of $35 million required for continued inclusion on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(2). The Company was provided 180 calendar days, or until September 3, 2024, to regain compliance with the rule. The Company did not regain compliance with the rule during the allotted time period. Accordingly, on September 10, 2024, the Company received a staff determination letter from the Nasdaq Listing Qualifications Department, stating that unless the Company timely requested a hearing before a Nasdaq Hearings Panel (the “Panel”) to appeal the staff determination, the Company’s securities would be subject to suspension and delisting. The Company timely requested a hearing before the Panel, which was held on October 29, 2024. On November 8, 2024, the Panel granted the Company an extension, until January 31, 2025, to regain compliance with the Nasdaq continued listing standards. During the extension granted by the Panel, the Company’s common stock and Series Z warrants will continue to trade uninterrupted under the symbol “PAVM” and “PAVMZ”, respectively. During the nine months ended September 30, 2024 a total of 34,332 Stock-Based Compensation In the nine months ended September 30, 2024, 574,424 980 Debt In the nine months ended September 30, 2024, the Company sold 627,302 shares through their at-the-market equity facility for net proceeds of approximately $ 977 , after payment of 3 % commissions. In the nine months ended September 30, 2024, the Company issued 200,809 200 PAVmed Distribution of Lucid Diagnostics Common Stock to Shareholders On February 15, 2024, the Company distributed by special dividend to the Company stockholders 3,331,747 38 100 The Company’s distribution of Lucid common stock to PAVmed stockholders, constituted an “Extraordinary Dividend” as defined in the Warrant Agreement. Accordingly, as a result of the distribution, pursuant to Section 4.3 of the Warrant Agreement, the Warrant Price has been decreased by $ 0.52 0.37709668 23.48 Common Stock Purchase Warrants As of September 30, 2024 and December 31, 2023, Series Z Warrants outstanding totaled 11,937,450 795,830 23.48 24.00 0.52

Noncontrolling Interest

Noncontrolling Interest	9 Months Ended
	Sep. 30, 2024
Noncontrolling Interest [Abstract]
Noncontrolling Interest	Note 15 — Noncontrolling Interest The noncontrolling interest (“NCI”) included as a component of consolidated total stockholders’ equity is summarized for the periods indicated as follows: Schedule of Noncontrolling Interest of Stockholders' Equity September 30, 2024 NCI – equity - December 31, 2023 $ 29,813 Net loss attributable to NCI (11,075 ) Impact of subsidiary equity transactions (4,414 ) Lucid Diagnostics proceeds from issuance of preferred stock Series A-1 5,670 Lucid Diagnostics exchange of preferred stock Series A and Series A-1 (24,294 ) Lucid Diagnostics issuance through exchange - Series B and Series B-1 31,790 Lucid Diagnostics issuance through sale - Series B and Series B-1 24,129 Lucid Diagnostics deemed dividend on preferred stock (7,496 ) Lucid Diagnostics issuance of common stock for settlement of vendor service agreement 401 Lucid Diagnostics 2018 Equity Plan stock option exercise 4 Lucid Diagnostics Employee Stock Purchase Plan Purchase 353 Conversion of Lucid Diagnostics common stock for Senior Secured Convertible Debt 3,801 Stock-based compensation expense - Lucid Diagnostics 2018 Equity Plan 2,771 Stock-based compensation expense - Veris Health 2021 Equity Plan 368 Deconsolidation of Lucid (56,339 ) NCI – equity - September 30, 2024 $ (4,518 ) The consolidated NCI presented above is with respect to the Company’s consolidated subsidiaries as a component of consolidated total stockholders’ equity as of September 30, 2024 and December 31, 2023; and the recognition of a net loss attributable to the NCI in the unaudited condensed consolidated statement of operations for the periods beginning on the acquisition date of the respective subsidiaries. Lucid Diagnostics — Deconsolidation As of September 30, 2024, there were 51,597,718 31,302,444 On September 10, 2024, following preferred equity transactions completed by Lucid earlier in 2024 and the termination of voting proxies entered into between PAVmed and certain shareholders of Lucid, PAVmed’s voting interest in the Company was reduced to less than 50.0%, resulting in the loss of a controlling financial interest. However, PAVmed retains the ability to exercise significant influence over Lucid. Upon deconsolidation, the Company’s ownership of 31,302,444 shares of Lucid Diagnostics common stock was valued at $25.1 million, which resulted in a gain on deconsolidation of $72.3 million in the accompanying unaudited condensed consolidated statements of operations for the three and nine months ended September 30, 2024. Lucid Diagnostics — Intercompany Obligation Settlement; Special Distribution On January 26, 2024 PAVmed elected to receive payment of $ 4,675 3,331,771 3,331,747 Lucid Diagnostics — Convertible Preferred Stock Offerings On March 7, 2023, Lucid issued 13,625 1,000 1.394 20 13.625 Note 15 — Noncontrolling Interest On March 13, 2024, Lucid issued an additional 5,670 5.67 On March 13, 2024, Lucid issued 44,285 1.2444 5,670 5.67 18.1 As a result of 100 On May 6, 2024, Lucid issued approximately 11,634 0.7228 11.6 Lucid Diagnostics — Deemed Dividend on Series A and Series A-1 Convertible Preferred Stock Exchange Offer The fair value of the consideration given in the form of the issue of 31,790 shares of Lucid Series B Convertible Preferred Stock, with such fair value recognized as the carrying value of such issued shares of Lucid Series B Convertible Preferred Stock, as compared to the carrying value of the extinguished Lucid Series A and Lucid Series A-1 Convertible Preferred Stock (carrying value of $ 24,294 ), resulting in an excess of fair value of $ 7.5 million recognized as a deemed dividend charged to accumulated deficit in the unaudited condensed consolidated balance sheet on March 13, 2024, with such deemed dividend included as a component of net loss attributable to common stockholders, summarized as follows: Schedule of Net Loss Attributable to Common Stockholders Lucid Series B Convertible Preferred Stock Issuance and Series A/A-1 Exchange Offer March 13, 2024 Fair Value - 31,790 $ 31,790 Fair Value - 31,790 $ 31,790 Less: Carrying value related to Lucid Series A and Lucid Series A-1 Preferred Stock Exchanged for Lucid Series B Preferred Stock (of 24,295 (24,294 ) Deemed Dividend Charged to Accumulated Deficit $ 7,496

Net Income (Loss) Per Share

Net Income (Loss) Per Share	9 Months Ended
	Sep. 30, 2024
Earnings Per Share [Abstract]
Net Income (Loss) Per Share	Note 16 — Net Income (Loss) Per Share The Net income (loss) per share - attributable to PAVmed Inc. - basic and diluted and Net income (loss) per share - attributable to PAVmed Inc. common stockholders - basic and diluted - for the respective periods indicated - is as follows: Schedule of Comparison of Basic and Fully Diluted Net Loss Per Share 2024 2023 2024 2023 Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 Numerator Net income (loss) - before noncontrolling interest $ 60,711 $ (21,750 ) $ 27,285 $ (61,855 ) Net income (loss) attributable to noncontrolling interest 3,688 4,079 11,075 11,716 Net income (loss) - as reported, attributable to PAVmed Inc. $ 64,399 $ (17,671 ) $ 38,360 $ (50,139 ) Series B Convertible Preferred Stock dividends – earned $ (83 ) $ (77 ) $ (244 ) $ (226 ) Deemed dividend on Subsidiary Preferred Stock attributable to the noncontrolling interests $ — $ — $ (7,496 ) $ — Net income (loss) attributable to PAVmed Inc. common stockholders used in basic EPS calculation $ 64,316 $ (17,748 ) $ 30,620 $ (50,365 ) Fair Value Adjustment for diluted EPS calculation $ (240 ) $ — $ 3,378 $ — Net income (loss) attributable to PAVmed Inc. common stockholders used in dilutive EPS calculation $ 64,076 $ (17,748 ) $ 33,998 $ (50,365 ) Denominator Weighted average common shares outstanding, basic 10,005,379 7,462,751 9,286,999 6,967,764 Weighted average common shares outstanding, diluted 44,475,638 7,462,751 43,069,449 6,967,764 Net income (loss) per share ( 1) Net income (loss) per share attributable to PAVmed Inc. common stockholders, basic (1) $ 6.43 $ (2.38 ) $ 3.30 $ (7.23 ) Net income (loss) per share attributable to PAVmed Inc. common stockholders, diluted (1) $ 1.44 $ (2.38 ) $ 0.79 $ (7.23 ) (1) - Convertible preferred stock and restricted stock awards would potentially be considered a participating security under the two-class method of calculating net income (loss) per share. For periods where losses are presented, such holders are not contractually obligated to share in the losses, there is no impact on the Company’s net income (loss) per share calculation for the periods indicated. The common stock equivalents have been excluded from the computation of diluted weighted average shares outstanding as their inclusion would be anti-dilutive, are as follows: The Series B Convertible Preferred Stock dividends earned as of each of the respective years noted, are included in the calculation of basic and diluted net loss attributable to PAVmed common stockholders for each respective period presented. Notwithstanding, the Series B Convertible Preferred Stock dividends are recognized as a dividend payable only upon the dividend being declared payable by the Company’s board of directors. Basic weighted-average number of shares of common stock outstanding for the nine month periods ended September 30, 2024 and 2023 include the shares of the Company issued and outstanding during such periods, each on a weighted average basis. The basic weighted average number of shares of common stock outstanding excludes common stock equivalent incremental shares, while diluted weighted average number of shares outstanding includes such incremental shares. However, as the Company was in a loss position for the three and nine month periods ended September 30, 2023, basic and diluted weighted average shares outstanding are the same, as the inclusion of the incremental shares would be anti-dilutive. The common stock equivalents excluded from the computation of diluted weighted average shares outstanding are as follows: Schedule of Antidilutive Securities Excluded from Computation of Diluted Earnings Per Share 2024 2023 September 30, 2024 2023 Stock options 1,233,107 1,138,632 Restricted stock awards — 70,528 Series Z Warrants 795,830 795,830 Series B Convertible Preferred Stock — 85,307 Total 2,028,937 2,090,297 The total stock options and restricted stock awards are inclusive of 60,054 33,391

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2024
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited condensed consolidated financial statements of PAVmed and those of its wholly owned subsidiaries and variable interest entities have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”), and applicable rules and regulations of the United States Securities and Exchange Commission (“SEC”). All intercompany transactions and balances have been eliminated in consolidation. The Company has a controlling financial interest in Veris Health Inc., with the corresponding noncontrolling interest included as a separate component of consolidated stockholders’ equity (deficit), including the recognition in the unaudited condensed consolidated statement of operations of a net loss attributable to the noncontrolling interest based on the respective minority-interest equity ownership of each subsidiary. As of September 10, 2024, PAVmed ceased to have a controlling financial interest in Lucid Diagnostics and therefore PAVmed’s consolidated results of operations include Lucid Diagnostics’ results of operations only through that date. The deconsolidation of Lucid Diagnostics has resulted in a gain recognized in PAVmed’s statement of operations for the periods ended September 30, 2024. Moving forward, PAVmed will account for its investment in Lucid Diagnostics using the equity method and the fair value option. See below and Note 4, Equity Method Investment Noncontrolling Interest As permitted under SEC rules, certain footnotes or other financial information normally required by U.S. GAAP have been condensed or omitted. The balance sheet as of December 31, 2023 has been derived from audited consolidated financial statements at such date. The accompanying unaudited condensed consolidated financial statements have been prepared on the same basis as the Company’s annual consolidated financial statements, and in the opinion of management, include all adjustments, consisting only of routine recurring adjustments, necessary for a fair statement of the Company’s unaudited condensed consolidated financial information. The unaudited condensed consolidated results of operations for the three and nine months ended September 30, 2024 are not necessarily indicative of the consolidated results to be expected for the year ending December 31, 2024 or for any other interim period or for any other future periods. The accompanying unaudited condensed consolidated financial statements and related unaudited condensed consolidated financial information should be read in conjunction with the Company’s audited consolidated financial statements and related notes thereto as of and for the year ended December 31, 2023 included in the Company’s Annual Report on Form 10-K as filed with the SEC on March 25, 2024. All amounts in the accompanying unaudited condensed consolidated financial statements and the notes thereto are presented in thousands of dollars, if not otherwise noted as being presented in millions of dollars, except for shares and per share amounts.
Cash	Cash The Company maintains its cash at a major financial institution with high credit quality. At times, the balance of its cash deposits may exceed federally insured limits. The Company has not experienced losses on deposits with commercial banks and financial institutions which exceed federally insured limits. Included in the Company’s cash as of September 30, 2024 and December 31, 2023 is $ 299
Use of Estimates	Use of Estimates In preparing the unaudited condensed consolidated financial statements in conformity with U.S. GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and the determination of corresponding carrying value reserve, if any, and liabilities and the disclosure of contingent losses, as of the date of the unaudited condensed consolidated financial statements, as well as the reported amounts of revenue and expenses during the reporting period. Significant estimates in these unaudited condensed consolidated financial statements include those related to the estimated fair value of debt obligations, stock-based equity awards, intangible assets and common stock purchase warrants. Other significant estimates include the estimated incremental borrowing rate, the provision or benefit for income taxes and the corresponding valuation allowance on deferred tax assets. Additionally, management’s assessment of the Company’s ability to continue as a going concern involves the estimation of the amount and timing of future cash inflows and outflows. On an ongoing basis, the Company evaluates its estimates and assumptions. The Company bases its estimates on historical experience and on various other assumptions believed to be reasonable. Due to inherent uncertainty involved in making estimates, actual results reported in future periods may be affected by changes in these estimates. Note 3 — Summary of Significant Accounting Policies
Revenue Recognition	Revenue Recognition Revenues are recognized when the satisfaction of the performance obligation occurs, in an amount that reflects the consideration the Company expects to collect in exchange for those services. The Company’s revenue was primarily generated by Lucid’s laboratory testing services utilizing its EsoGuard Esophageal DNA tests. The services were completed upon release of a patient’s test result to the ordering healthcare provider. Revenue recognized is inclusive of both variable consideration in connection with an individual patient’s third-party insurance coverage policy and fixed consideration in connection with a contracted services arrangement with an unrelated third party legal entity. To determine revenue recognition for the arrangements that the Company determines are within the scope of ASC 606, Revenue from Contracts with Customers, the Company performs the following five steps: (1) identify the contract(s) with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract and (5) recognize revenue when (or as) the entity satisfies a performance obligation. The key aspects considered by the Company include the following: Contracts Performance obligations Transaction price If the consideration derived from the contracts is deemed to be variable, the Company estimates the amount of consideration to which it will be entitled in exchange for the promised goods or services. The Company limits the amount of variable consideration included in the transaction price to the unconstrained portion of such consideration. In other words, the Company recognizes revenue up to the amount of variable consideration that is not subject to a significant reversal until additional information is obtained or the uncertainty associated with the additional payments or refunds is subsequently resolved. When the Company does not have significant historical experience or that experience has limited predictive value, the constraint over estimates of variable consideration may result in no revenue being recognized upon delivery of patient EsoGuard test results to the ordering healthcare provider. As such, the Company recognizes revenue up to the amount of variable consideration not subject to a significant reversal until additional information is obtained or the uncertainty associated with additional payments or refunds, if any, is subsequently resolved. Differences between original estimates and subsequent revisions, including final settlements, represent changes in estimated expected variable consideration, with the change in estimate recognized in the period of such revised estimate. With respect to a contracted service arrangement, the fixed consideration revenue is recognized on an as-billed basis upon delivery of the laboratory test report with realization of such fixed consideration deemed probable based upon actual historical experience. Allocate transaction price Practical Expedients Note 3 — Summary of Significant Accounting Policies
Equity Method Investments	Equity Method Investments Businesses that are not consolidated, but over which PAVmed exercises significant influence, are accounted for under the equity method of accounting. The determination as to whether or not PAVmed exercises significant influence with respect to a company depends on an evaluation of several factors, including, among others, representation on the company’s board of directors and equity ownership level, which is generally between a 20 50
Fair Value Option (“FVO”) Election	Fair Value Option (“FVO”) Election Under a Securities Purchase Agreement dated March 31, 2022, the Company issued a Senior Secured Convertible Note dated April 4, 2022, referred to herein as the “April 2022 Senior Convertible Note”, and a Senior Secured Convertible Note dated September 8, 2022, referred to herein as the “September 2022 Senior Convertible Note”, which are accounted under the “fair value option election” as discussed below. Under a Securities Purchase Agreement dated March 13, 2023, Lucid Diagnostics issued a Senior Secured Convertible Note dated March 21, 2023, referred to herein as the “Lucid March 2023 Senior Convertible Note”, which is accounted under the “fair value option election”, through September 10, 2024, the date of Lucid’s deconsolidation from PAVmed’s results of operations, as discussed below. Under Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 815, Derivative and Hedging Alternatively, FASB ASC Topic 825, Financial Instruments See Note 10, Financial Instruments Fair Value Measurements Debt From and after September 10, 2024, the date of Lucid’s deconsolidation from PAVmed’s results of operation, the Company’s investment in Lucid is treated as an equity method investment accounted for using the fair value option. Shares of Lucid Diagnostics common stock have a readily determinable fair value classified as Level 1, in which the fair value is determined based upon quoted market prices in an active market.
Recent Accounting Standards Updates Not Yet Adopted	Recent Accounting Standards Updates Not Yet Adopted In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740)—Improvements to Income Tax Disclosures (“ASU 2023-09”), which is intended to enhance the transparency and decision usefulness of income tax disclosures. The amendments in ASU 2023-09 provide for enhanced income tax information primarily through changes to the rate reconciliation and income taxes paid information. ASU 2023-09 is effective for the Company prospectively to all annual periods beginning after December 15, 2024. Early adoption is permitted. The Company does not expect the standard to have a significant impact on its unaudited condensed consolidated financial statements. In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280)—Improvements to Reportable Segment Disclosures (“ASU 2023-07”), which require public companies disclose significant segment expenses and other segment items on an annual and interim basis and to provide in interim periods all disclosures about a reportable segment’s profit or loss and assets that are currently required annually. The guidance is effective for public entities for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The guidance is applied retrospectively to all periods presented in the financial statements, unless it is impracticable. The Company is currently evaluating the impact this update will have on its unaudited condensed consolidated financial statements and disclosures, however the Company does not expect the standard to have a significant impact. Note 3 — Summary of Significant Accounting Policies In October 2023, the FASB issued ASU No. 2023-06, Disclosure Improvements: Codification Amendments in Response to the SEC’s Disclosure Update and Simplification Initiative. This update modifies the disclosure or presentation requirements of a variety of topics in the Accounting Standards Codification to conform with certain SEC amendments in Release No. 33-10532, Disclosure Update and Simplification. The amendments in this update should be applied prospectively, and the effective date for each amendment will be the date on which the SEC’s removal of that related disclosure from Regulation S-X or S-K becomes effective. However, if the SEC has not removed the related disclosure from its regulations by June 30, 2027, the amendments will be removed from the Codification and not become effective. Early adoption is prohibited. The Company is currently evaluating the impact this update will have on its unaudited condensed consolidated financial statements and disclosures.

Equity Method Investment (Table

Equity Method Investment (Tables)	9 Months Ended
	Sep. 30, 2024
Equity Method Investments and Joint Ventures [Abstract]
Schedule of Deconsolidation of Net Assets	Schedule of Deconsolidation of Net Assets Assets: Current assets: Cash $ 16,479 Prepaid expenses, deposits, and other current assets 3,474 Total current assets 19,953 Fixed assets, net 964 Operating lease right-of-use assets 2,871 Intangible assets, net 877 Other assets 379 Total assets 25,044 Liabilities: Current liabilities: Accounts payable 1,069 Accrued expenses and other current liabilities 1,674 Operating lease liabilities, current portion 865 Senior Secured Convertible Notes - at fair value 10,268 Total current liabilities 13,876 Operating lease liabilities, less current portion 2,011 Total liabilities 15,887 Net Assets of Lucid Diagnostics at September 10, 2024 $ 9,157
Schedule of Gain on Deconsolidation	Schedule of Gain on Deconsolidation Investment in former Consolidated Subsidiary (Fair Value of Lucid common stock) $ 25,105 Add: Noncontrolling interest - Lucid 56,339 Less: Net Assets of Former Consolidated Subsidiary - Lucid (9,157 ) Gain on Deconsolidation of Lucid $ 72,287
Schedule of Aggregate Information From the Financial Statements	Schedule of Aggregate Information From the Financial Statements September 30, 2024 Cash $ 14,489 Other current assets 2,335 Non-current assets 5,774 Total assets 22,598 Current liabilities 14,249 Non-current liabilities 2,011 Shareholders’ deficit 6,338 Total liabilities and stockholders’ deficit $ 22,598 Three months ended September 30, 2024 July 1, 2024 - September 10, 2024 September 11, 2024 - September 30, 2024 Total Revenue $ 942 $ 230 $ 1,172 Net income (loss) $ (9,039 ) $ (3,332 ) $ (12,371 ) Nine months ended September 30, 2024 January 1, 2024 - September 10, 2024 September 11, 2024 - September 30, 2024 Total Revenue $ 2,919 $ 230 $ 3,149 Net income (loss) $ (38,152 ) $ (3,332 ) $ (41,484 )

Prepaid Expenses, Deposits, a_2

Prepaid Expenses, Deposits, and Other Current Assets (Tables)	9 Months Ended
	Sep. 30, 2024
Prepaid Expenses Deposits And Other Current Assets
Schedule of Prepaid Expenses and Other Current Assets	Prepaid expenses and other current assets consisted of the following as of: Schedule of Prepaid Expenses and Other Current Assets September 30, 2024 December 31, 2023 Advanced payments to service providers and suppliers $ 181 $ 739 Prepaid insurance 420 848 Deposits 480 2,672 Veris Box supplies 262 261 Total prepaid expenses, deposits and other current assets $ 1,343 $ 4,520

Leases (Tables)

Leases (Tables)	9 Months Ended
	Sep. 30, 2024
Leases
Schedule of Future Minimum Lease Payments for Operating Leases	The Company’s future lease payments as of September 30, 2024, which are presented as operating lease liabilities, current portion and operating lease liabilities, less current portion on the Company’s unaudited condensed consolidated balance sheets are as follows: Schedule of Future Minimum Lease Payments for Operating Leases 2024 (remainder of year) $ 174 2025 708 2026 724 2027 594 2028 471 Thereafter 848 Total lease payments $ 3,519 Less: imputed interest (640 ) Present value of lease liabilities $ 2,879
Schedule of Supplemental Balance Sheet Information Related to Cash and Non-cash Activities with Leases	Supplemental disclosure of cash flow information related to the Company’s cash and non-cash activities with its leases are as follows: Schedule of Supplemental Balance Sheet Information Related to Cash and Non-cash Activities with Leases 2024 2023 Nine Months Ended September 30, 2024 2023 Cash paid for amounts included in the measurement of lease liabilities Operating cash flows from operating leases $ 1,407 $ 1,080 Non-cash investing and financing activities Right-of-use assets obtained in exchange for new operating lease liabilities $ — $ 2,728 Weighted-average remaining lease term - operating leases (in years) 5.25 6.68 Weighted-average discount rate - operating leases 7.875 % 7.875 %

Intangible Assets, net (Tables)

Intangible Assets, net (Tables)	9 Months Ended
	Sep. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Intangible Assets, Less Accumulated Amortization	Intangible assets, less accumulated amortization, consisted of the following as of: Schedule of Intangible Assets, Less Accumulated Amortization Estimated Useful Life September 30, 2024 December 31, 2023 Defensive asset 60 $ — $ 2,105 Laboratory licenses and certifications and laboratory information management software 24 — 3,200 Other 1 year 70 70 Total Intangible assets 70 5,375 Less Accumulated Amortization (70 ) (3,951 ) Intangible Assets, net $ — $ 1,424

Financial Instruments Fair Va_2

Financial Instruments Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2024
Fair Value Disclosures [Abstract]
Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis	The fair value hierarchy table for the periods indicated is as follows: Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis Fair Value Measurement on a Recurring Basis at Reporting Date Using 1 Level-1 Inputs Level-2 Inputs Level-3 Inputs Total September 30, 2024 Assets: Investment in Lucid Diagnostics, Inc common stock $ 25,511 $ — $ — $ 25,511 Total assets at fair value $ 25,511 $ — $ — $ 25,511 Liabilities: Senior Secured Convertible Note - April 2022 — — 19,850 19,850 Senior Secured Convertible Note - September 2022 — — 12,200 12,200 Total liabilities at fair value $ — $ — $ 32,050 $ 32,050 Level-1 Inputs Level-2 Inputs Level-3 Inputs Total December 31, 2023 Liabilities: Senior Secured Convertible Note - April 2022 $ — $ — $ 19,000 $ 19,000 Senior Secured Convertible Note - September 2022 — — 11,250 11,250 Lucid Senior Secured Convertible Note - March 2023 — — 13,950 13,950 Total liabilities at fair value $ — $ — $ 44,200 $ 44,200 1 There were no transfers between the respective Levels during the nine months ended September 30, 2024.
Schedule of Fair Value Assumption Used	The estimated fair value of the April 2022 Senior Convertible Note and the September 2022 Senior Convertible Note as of September 30, 2024 and the estimated fair value of the April 2022 Senior Convertible Note, the September 2022 Senior Convertible Note and the Lucid March 2023 Senior Convertible Note as of December 31, 2023, were computed using a Monte Carlo simulation of the present value of its cash flows using a synthetic credit rating analysis and a required rate-of-return, using the following assumptions: Schedule of Fair Value Assumption Used April 2022 Senior September 2022 Senior Fair Value $ 19,850 $ 12,200 Face value principal payable $ 17,602 $ 7,627 Required rate of return 9.000 % 8.800 % Conversion Price $ 75.00 $ 75.00 Value of common stock $ 1.23 $ 1.23 Expected term (years) 0.51 0.94 Volatility 160.00 % 160.00 % Risk free rate 4.28 % 3.95 % Dividend yield — % — % April 2022 Senior September 2022 Lucid March 2023 Fair Value $ 19,000 $ 11,250 $ 13,950 Face value principal payable $ 17,602 $ 9,062 $ 11,019 Required rate of return 10.00 10.50 % 10.00 10.20 % 10.00 % Conversion Price $ 75.00 $ 75.00 $ 5.00 Value of common stock $ 4.12 $ 4.12 $ 1.41 Expected term (years) 0.26 1.26 0.69 1.69 1.22 Volatility 85.00 % 85.00 % 60.00 % Risk free rate 4.54 5.25 % 4.31 4.96 % 4.56 % Dividend yield — % — % — %

Debt (Tables)

Debt (Tables)	9 Months Ended
	Sep. 30, 2024
Debt Disclosure [Abstract]
Summary of Outstanding Debt	The fair value and face value principal outstanding of the Senior Convertible Notes as of the dates indicated are as follows: Summary of Outstanding Debt Contractual Maturity Date Stated Interest Rate Conversion Face Value Fair Value April 2022 Senior Convertible Note April 4, 2025 7.875 % $ 75.00 $ 17,602 $ 19,850 September 2022 Senior Convertible Note September 8, 2025 7.875 % $ 75.00 7,627 12,200 Balance as of September 30, 2024 $ 25,229 $ 32,050 Contractual Maturity Date Stated Interest Rate Conversion Price per Share Face Value Principal Outstanding Fair Value April 2022 Senior Convertible Note April 4, 2025 7.875 % $ 75.00 $ 17,602 $ 19,000 September 2022 Senior Convertible Note September 8, 2025 7.875 % $ 75.00 9,062 11,250 Lucid March 2023 Senior Convertible Note March 21, 2025 7.875 % $ 5.00 11,019 13,950 Balance as of December 31, 2023 $ 37,683 $ 44,200
Schedule of Changes in Fair Value of Debt	The changes in the fair value of debt during the three and nine month periods ended September 30, 2024 is as follows: Schedule of Changes in Fair Value of Debt April 2022 Senior Convertible Note September 2022 Senior Convertible Note Lucid March 2023 Senior Convertible Note Sum of Balance Sheet Fair Value Components Other Income (expense) Fair Value - June 30, 2024 $ 19,200 $ 13,600 $ 11,200 $ 44,000 $ — Face value principal – issue date Fair value adjustment – issue date Installment repayments – common stock — (455 ) (797 ) (1,252 ) — Non-installment payments – common stock — (55 ) (135 ) (190 ) — Deconsolidation of Lucid Diagnostics — — (10,268 ) (10,268 ) — Change in fair value 650 (890 ) — (240 ) 240 Fair Value at September 30, 2024 $ 19,850 $ 12,200 $ — $ 32,050 - Other Income (Expense) - Change in fair value – three month period ended September 30, 2024 $ 240 April 2022 Senior Convertible Note September 2022 Senior Convertible Note Lucid March 2023 Senior Convertible Note Sum of Balance Sheet Fair Value Components Other Income (expense) Fair Value - December 31, 2023 $ 19,000 $ 11,250 $ 13,950 $ 44,200 $ — Installment repayments – common stock — (1,435 ) (2,005 ) (3,440 ) — Non-installment payments – common stock — (143 ) (787 ) (930 ) — Deconsolidation of Lucid Diagnostics — — (10,268 ) (10,268 ) — Change in fair value 850 2,528 (890 ) 2,488 (2,488 ) Fair Value at September 30, 2024 $ 19,850 $ 12,200 $ — $ 32,050 - Other Income (Expense) - Change in fair value – nine month period ended September 30, 2024 $ (2,488 ) Note 11 — Debt The changes in the fair value of debt during the three and nine month periods ended September 30, 2023 is as follows: April 2022 Senior Convertible Note September 2022 Senior Convertible Note Lucid March 2023 Senior Convertible Note Sum of Balance Sheet Fair Value Components Other Income (expense) Fair Value - June 30, 2023 $ 19,530 $ 11,850 $ 11,610 $ 42,990 $ — Installment repayments – common stock (952 ) (1,207 ) (92 ) (2,251 ) — Non-installment payments – common stock (41 ) (51 ) (49 ) (141 ) — Change in fair value 863 508 3,021 4,392 (4,392 ) Fair Value at September 30, 2023 $ 19,400 $ 11,100 $ 14,490 $ 44,990 - Other Income (Expense) - Change in fair value – three month period ended September 30, 2023 $ (4,392 ) April 2022 Senior Convertible Note September 2022 Senior Convertible Note Lucid March 2023 Senior Convertible Note Sum of Balance Sheet Fair Value Components Other Income (expense) Fair Value - December 31, 2022 $ 22,000 $ 11,650 $ — $ 33,650 $ — Fair Value - Beginning of Period $ 22,000 $ 11,650 $ — $ 33,650 $ — Face value principal – issue date — — 11,111 11,111 — Fair value adjustment – issue date — — 789 789 (789 ) Installment repayments – common stock (3,895 ) (1,207 ) (92 ) (5,194 ) — Non-installment payments – common stock (249 ) (51 ) (49 ) (349 ) — Change in fair value 1,544 708 2,731 4,983 (4,983 ) Fair Value at September 30, 2023 $ 19,400 $ 11,100 $ 14,490 $ 44,990 - Fair Value - Ending of Period $ 19,400 $ 11,100 $ 14,490 $ 44,990 - Other Income (Expense) - Change in fair value – nine month period ended September 30, 2023 $ (5,772 )

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2024
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Schedule of Stock-Based Compensation Expense	The consolidated stock-based compensation expense recognized by each of PAVmed and (through September 10, 2024, the date of PAVmed’s deconsolidation of Lucid) Lucid Diagnostics for both the PAVmed 2014 Equity Plan and the Lucid Diagnostics 2018 Equity Plan, with respect to stock options and restricted stock awards as discussed above, for the periods indicated, was as follows: Schedule of Stock-Based Compensation Expense 2024 2023 2024 2023 Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 Cost of revenue $ 32 $ 32 $ 112 $ 86 Sales and marketing expenses 292 403 1,082 1,302 General and administrative expenses 1,426 1,499 3,717 6,761 Research and development expenses 181 311 805 1,022 Total stock-based compensation expense $ 1,931 $ 2,245 $ 5,716 $ 9,171
Schedule of Stock-Based Compensation Expense Recognized by Lucid Diagnostics	Schedule of Stock-Based Compensation Expense Recognized by Lucid Diagnostics 2024 2023 2024 2023 Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 Lucid Diagnostics 2018 Equity Plan – cost of revenue $ 24 $ 16 $ 81 $ 44 Lucid Diagnostics 2018 Equity Plan – sales and marketing 252 228 849 697 Lucid Diagnostics 2018 Equity Plan – general and administrative 548 721 1,484 4,069 Lucid Diagnostics 2018 Equity Plan – research and development 98 67 356 204 PAVmed 2014 Equity Plan - cost of revenue 9 10 30 26 PAVmed 2014 Equity Plan - sales and marketing 18 106 136 359 PAVmed 2014 Equity Plan - general and administrative 1 7 5 170 PAVmed 2014 Equity Plan - research and development 5 97 148 290 Total stock-based compensation expense – recognized by Lucid Diagnostics $ 955 $ 1,252 $ 3,089 $ 5,859 Total stock-based compensation expense $ 955 $ 1,252 $ 3,089 $ 5,859
Schedule of Unrecognized Compensation Expense	The consolidated unrecognized stock-based compensation expense and weighted average remaining requisite service period with respect to stock options and restricted stock awards issued under the PAVmed 2014 Equity Plan, as discussed above, is as follows: Schedule of Unrecognized Compensation Expense Unrecognized Expense Weighted Average Remaining Service Period (Years) PAVmed 2014 Equity Plan Stock Options $ 1,377 1.5 Restricted Stock Awards $ 397 2.2
2014 Equity Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Schedule of Summarizes Information About Stock Options	PAVmed stock options granted under the PAVmed 2014 Equity Plan and stock options granted outside such plan are summarized as follows: Schedule of Summarizes Information About Stock Options Number of Stock Options Weighted Average Exercise Price Remaining Contractual Term (Years) Intrinsic Value (2) Outstanding stock options at December 31, 2023 1,192,458 $ 26.18 7.3 $ — Granted (1) 79,500 $ 2.28 Exercised — $ — Forfeited (38,851 ) $ 13.47 Outstanding stock options at September 30, 2024 (3) 1,233,107 $ 25.04 5.9 $ — Vested and exercisable stock options at September 30, 2024 956,977 $ 30.27 5.1 $ — (1) Stock options granted under the PAVmed 2014 Equity Plan and those granted outside such plan generally vest one-third in one year then ratably over the next eight quarters, and have a ten-year contractual term from date-of-grant. (2) The intrinsic value is computed as the difference between the quoted price of the PAVmed common stock on each of September 30, 2024 and December 31, 2023 and the exercise price of the underlying PAVmed stock options, to the extent such quoted price is greater than the exercise price. (3) The outstanding stock options presented in the table above are inclusive of 60,054
Schedule of Restricted Stock Award Activity	PAVmed restricted stock awards granted under the PAVmed 2014 Equity Plan and restricted stock awards granted outside such plan are summarized as follows: Schedule of Restricted Stock Award Activity Number of Restricted Stock Awards Weighted Average Grant Date Fair Value Unvested restricted stock awards as of December 31, 2023 70,527 $ 38.77 Granted 390,000 1.85 Vested (135,080 ) 2.00 Forfeited — — Unvested restricted stock awards as of September 30, 2024 325,447 $ 9.79
Schedule of Fair Values of Stock Options Granted Using Black-scholes Valuation Model Assumptions	Schedule of Fair Values of Stock Options Granted Using Black-scholes Valuation Model Assumptions Nine Months Ended September 30, 2024 2023 Expected term of stock options (in years) 5.8 5.7 Expected stock price volatility 90 % 88 % Risk free interest rate 4.3 % 3.7 % Expected dividend yield — % — %
2018 Equity Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Schedule of Summarizes Information About Stock Options	Lucid Diagnostics stock options granted under the Lucid Diagnostics 2018 Equity Plan and stock options granted outside such plan are summarized as follows: Schedule of Summarizes Information About Stock Options Number of Stock Options Weighted Average Exercise Price Remaining Contractual Term (Years) Intrinsic Value (2) Outstanding stock options at December 31, 2023 5,504,383 $ 2.00 8.5 $ 765 Granted (1) 3,604,000 $ 1.22 Exercised (3,333 ) $ 1.31 Forfeited (417,501 ) $ 1.63 Outstanding stock options at September 10, 2024 (3) 8,687,549 $ 1.69 8.3 $ 191 Vested and exercisable stock options at September 10, 2024 3,084,682 $ 2.25 7.1 $ 191 (1) Stock options granted under the Lucid Diagnostics 2018 Equity Plan and those granted outside such plan generally vest one-third in one year then ratably over the next eight quarters, and have a ten-year contractual term from date-of-grant. (2) The intrinsic value is computed as the difference between the quoted price of the Lucid Diagnostics common stock on each of September 10, 2024 and December 31, 2023 and the exercise price of the underlying Lucid Diagnostics stock options, to the extent such quoted price is greater than the exercise price. (3) The outstanding stock options presented in the table above are inclusive of 523,300
Schedule of Restricted Stock Award Activity	Lucid Diagnostics restricted stock awards granted under the Lucid Diagnostics 2018 Equity Plan and restricted stock awards granted outside such plan are summarized as follows: Schedule of Restricted Stock Award Activity Number of Restricted Stock Awards Weighted Average Grant Date Fair Value Unvested restricted stock awards as of December 31, 2023 2,337,440 $ 8.99 Granted 1,600,000 1.03 Vested (26,912 ) 4.56 Forfeited (13,088 ) 4.56 Unvested restricted stock awards as of September 10, 2024 3,897,440 $ 5.77
Schedule of Fair Values of Stock Options Granted Using Black-scholes Valuation Model Assumptions	Schedule of Fair Values of Stock Options Granted Using Black-scholes Valuation Model Assumptions Nine Months Ended September 30, 2024 2023 Expected term of stock options (in years) 5.7 5.6 Expected stock price volatility 73 % 75 % Risk free interest rate 4.3 % 3.7 % Expected dividend yield — % — %

Noncontrolling Interest (Tables

Noncontrolling Interest (Tables)	9 Months Ended
	Sep. 30, 2024
Noncontrolling Interest [Abstract]
Schedule of Noncontrolling Interest of Stockholders' Equity	The noncontrolling interest (“NCI”) included as a component of consolidated total stockholders’ equity is summarized for the periods indicated as follows: Schedule of Noncontrolling Interest of Stockholders' Equity September 30, 2024 NCI – equity - December 31, 2023 $ 29,813 Net loss attributable to NCI (11,075 ) Impact of subsidiary equity transactions (4,414 ) Lucid Diagnostics proceeds from issuance of preferred stock Series A-1 5,670 Lucid Diagnostics exchange of preferred stock Series A and Series A-1 (24,294 ) Lucid Diagnostics issuance through exchange - Series B and Series B-1 31,790 Lucid Diagnostics issuance through sale - Series B and Series B-1 24,129 Lucid Diagnostics deemed dividend on preferred stock (7,496 ) Lucid Diagnostics issuance of common stock for settlement of vendor service agreement 401 Lucid Diagnostics 2018 Equity Plan stock option exercise 4 Lucid Diagnostics Employee Stock Purchase Plan Purchase 353 Conversion of Lucid Diagnostics common stock for Senior Secured Convertible Debt 3,801 Stock-based compensation expense - Lucid Diagnostics 2018 Equity Plan 2,771 Stock-based compensation expense - Veris Health 2021 Equity Plan 368 Deconsolidation of Lucid (56,339 ) NCI – equity - September 30, 2024 $ (4,518 )
Schedule of Net Loss Attributable to Common Stockholders	Schedule of Net Loss Attributable to Common Stockholders Lucid Series B Convertible Preferred Stock Issuance and Series A/A-1 Exchange Offer March 13, 2024 Fair Value - 31,790 $ 31,790 Fair Value - 31,790 $ 31,790 Less: Carrying value related to Lucid Series A and Lucid Series A-1 Preferred Stock Exchanged for Lucid Series B Preferred Stock (of 24,295 (24,294 ) Deemed Dividend Charged to Accumulated Deficit $ 7,496

Net Income (Loss) Per Share (Ta

Net Income (Loss) Per Share (Tables)	9 Months Ended
	Sep. 30, 2024
Earnings Per Share [Abstract]
Schedule of Comparison of Basic and Fully Diluted Net Loss Per Share	The Net income (loss) per share - attributable to PAVmed Inc. - basic and diluted and Net income (loss) per share - attributable to PAVmed Inc. common stockholders - basic and diluted - for the respective periods indicated - is as follows: Schedule of Comparison of Basic and Fully Diluted Net Loss Per Share 2024 2023 2024 2023 Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 Numerator Net income (loss) - before noncontrolling interest $ 60,711 $ (21,750 ) $ 27,285 $ (61,855 ) Net income (loss) attributable to noncontrolling interest 3,688 4,079 11,075 11,716 Net income (loss) - as reported, attributable to PAVmed Inc. $ 64,399 $ (17,671 ) $ 38,360 $ (50,139 ) Series B Convertible Preferred Stock dividends – earned $ (83 ) $ (77 ) $ (244 ) $ (226 ) Deemed dividend on Subsidiary Preferred Stock attributable to the noncontrolling interests $ — $ — $ (7,496 ) $ — Net income (loss) attributable to PAVmed Inc. common stockholders used in basic EPS calculation $ 64,316 $ (17,748 ) $ 30,620 $ (50,365 ) Fair Value Adjustment for diluted EPS calculation $ (240 ) $ — $ 3,378 $ — Net income (loss) attributable to PAVmed Inc. common stockholders used in dilutive EPS calculation $ 64,076 $ (17,748 ) $ 33,998 $ (50,365 ) Denominator Weighted average common shares outstanding, basic 10,005,379 7,462,751 9,286,999 6,967,764 Weighted average common shares outstanding, diluted 44,475,638 7,462,751 43,069,449 6,967,764 Net income (loss) per share ( 1) Net income (loss) per share attributable to PAVmed Inc. common stockholders, basic (1) $ 6.43 $ (2.38 ) $ 3.30 $ (7.23 ) Net income (loss) per share attributable to PAVmed Inc. common stockholders, diluted (1) $ 1.44 $ (2.38 ) $ 0.79 $ (7.23 ) (1) - Convertible preferred stock and restricted stock awards would potentially be considered a participating security under the two-class method of calculating net income (loss) per share. For periods where losses are presented, such holders are not contractually obligated to share in the losses, there is no impact on the Company’s net income (loss) per share calculation for the periods indicated.
Schedule of Antidilutive Securities Excluded from Computation of Diluted Earnings Per Share	Schedule of Antidilutive Securities Excluded from Computation of Diluted Earnings Per Share 2024 2023 September 30, 2024 2023 Stock options 1,233,107 1,138,632 Restricted stock awards — 70,528 Series Z Warrants 795,830 795,830 Series B Convertible Preferred Stock — 85,307 Total 2,028,937 2,090,297

Liquidity and Going Concern (De

Liquidity and Going Concern (Details Narrative) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Revenues	$ 1,000		$ 3,000
Net loss attributable to common stockholders	64,316	$ (17,748)	30,620	$ (50,365)
Net cash flows used in operating activities			33,648	$ 40,162
Working capital	35,400		35,400
Current liabilities	32,050		32,050		$ 44,200
Cash	$ 800		$ 800

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Details Narrative) - USD ($) $ in Thousands	Sep. 30, 2024	Sep. 10, 2024	Dec. 31, 2023
Lucid Diagnostics Inc [Member] | Minimum [Member]
Variable Interest Entity [Line Items]
Equity method investment, ownership percentage	20%
Lucid Diagnostics Inc [Member] | Maximum [Member]
Variable Interest Entity [Line Items]
Equity method investment, ownership percentage	50%	50%
Letter of Credit [Member]
Variable Interest Entity [Line Items]
Cash	$ 299		$ 299

Schedule of Deconsolidation of

Schedule of Deconsolidation of Net Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Sep. 10, 2024	Dec. 31, 2023
Current assets:
Cash	$ 765		$ 19,639
Prepaid expenses, deposits, and other current assets	1,343		4,520
Total current assets	2,130		24,498
Fixed assets, net	216		1,783
Operating lease right-of-use assets	2,618		4,267
Intangible assets, net			1,424
Other assets	75		1,147
Total assets	30,550		33,119
Current liabilities:
Accounts payable	465		1,786
Accrued expenses and other current liabilities	4,543		6,626
Operating lease liabilities, current portion	499		1,565
Senior Secured Convertible Notes - at fair value	32,050		44,200
Total current liabilities	37,557		54,177
Operating lease liabilities, less current portion	2,380		2,960
Total liabilities	39,937		$ 57,137
Lucid Diagnostics Inc [Member]
Current assets:
Cash	14,489	$ 16,479
Prepaid expenses, deposits, and other current assets		3,474
Total current assets		19,953
Fixed assets, net		964
Operating lease right-of-use assets		2,871
Intangible assets, net		877
Other assets		379
Total assets	22,598	25,044
Current liabilities:
Accounts payable		1,069
Accrued expenses and other current liabilities		1,674
Operating lease liabilities, current portion		865
Senior Secured Convertible Notes - at fair value		10,268
Total current liabilities	$ 14,249	13,876
Operating lease liabilities, less current portion		2,011
Total liabilities		15,887
Net Assets of Lucid Diagnostics at September 10, 2024		$ 9,157

Schedule of Gain on Deconsolida

Schedule of Gain on Deconsolidation (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Add: Noncontrolling interest - Lucid			$ (56,339)
Gain on Deconsolidation of Lucid	$ 72,287		72,287
Lucid Diagnostics Inc [Member]
Investment in former Consolidated Subsidiary (Fair Value of Lucid common stock)			25,105
Add: Noncontrolling interest - Lucid			56,339
Less: Net Assets of Former Consolidated Subsidiary - Lucid			(9,157)
Gain on Deconsolidation of Lucid	$ 72,300		$ 72,287

Schedule of Aggregate Informati

Schedule of Aggregate Information From the Financial Statements (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Sep. 10, 2024	Dec. 31, 2023
Cash	$ 765		$ 765			$ 19,639
Total assets	30,550		30,550			33,119
Current liabilities	37,557		37,557			54,177
Shareholders’ deficit	(4,869)		(4,869)			(53,831)
Total liabilities and stockholders’ deficit	30,550		30,550			$ 33,119
Revenue	996	$ 791	2,985	$ 1,403
Net income (loss)	64,399	$ (17,671)	38,360	$ (50,139)
Lucid Diagnostics Inc [Member]
Cash	14,489		14,489		$ 16,479
Other current assets	2,335		2,335
Non-current assets	5,774		5,774
Total assets	22,598		22,598		25,044
Current liabilities	14,249		14,249		$ 13,876
Non-current liabilities	2,011		2,011
Shareholders’ deficit	6,338		6,338
Total liabilities and stockholders’ deficit	22,598		22,598
Revenue	1,172		3,149
Net income (loss)	(12,371)		(41,484)
Lucid Diagnostics Inc [Member] | July 1, 2024 - September 10, 2024 [Member]
Revenue	942
Net income (loss)	(9,039)
Lucid Diagnostics Inc [Member] | September 11, 2024 - September 30, 2024 [Member]
Revenue	230		230
Net income (loss)	$ (3,332)		(3,332)
Lucid Diagnostics Inc [Member] | January 1, 2024 - September 10, 2024 [Member]
Revenue			2,919
Net income (loss)			$ (38,152)

Equity Method Investment (Detai

Equity Method Investment (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands			1 Months Ended	3 Months Ended		9 Months Ended
	Sep. 27, 2024	Sep. 10, 2024	Sep. 30, 2024	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Ownership shares value				$ 284		$ 977	$ 1,166
Gain on deconsolidation				$ 72,287		$ 72,287
Intellectual Property [Member]
Assignment fee	$ 350
Common Stock [Member]
Ownership shares issues				294,003		627,302	155,384
Ownership shares value
Common Stock [Member] | Lucid Diagnostics Inc [Member]
The fair value of common price per shares		40%	40%	40%		40%
Lucid Diagnostics Inc [Member]
Ownership shares issues		31,302,444
Ownership shares value		$ 25,100
Gain on deconsolidation				$ 72,300		$ 72,287
Fair value of the companys investment		$ 25,100	$ 25,500	25,500		25,500
Unrealized gain loss on investments				400		400
Lucid Diagnostics Inc [Member] | Management Services Agreement [Member] | Board of Directors Chairman [Member]
Fee income			$ 700			$ 833
Increase in fee income				$ 1,050
Lucid Diagnostics Inc [Member] | Common Stock [Member]
The fair value of common price per shares		$ 0.802	$ 0.815	$ 0.815		$ 0.815
Lucid Diagnostics Inc [Member] | Maximum [Member]
Equity method investment, ownership percentage		50%	50%	50%		50%

Revenue from Contracts with C_2

Revenue from Contracts with Customers (Details Narrative) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Revenue from Contract with Customer [Abstract]
Revenue	$ 996	$ 791	$ 2,985	$ 1,403
Cost of revenue	$ 1,381	$ 1,779	$ 4,792	$ 4,809

Schedule of Prepaid Expenses an

Schedule of Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Prepaid Expenses Deposits And Other Current Assets
Advanced payments to service providers and suppliers	$ 181	$ 739
Prepaid insurance	420	848
Deposits	480	2,672
Veris Box supplies	262	261
Total prepaid expenses, deposits and other current assets	$ 1,343	$ 4,520

Schedule of Future Minimum Leas

Schedule of Future Minimum Lease Payments for Operating Leases (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Leases
2024 (remainder of year)	$ 174
2025	708
2026	724
2027	594
2028	471
Thereafter	848
Total lease payments	3,519
Less: imputed interest	(640)
Present value of lease liabilities	$ 2,879	$ 4,525

Schedule of Supplemental Balanc

Schedule of Supplemental Balance Sheet Information Related to Cash and Non-cash Activities with Leases (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Leases
Operating cash flows from operating leases	$ 1,407	$ 1,080
Right-of-use assets obtained in exchange for new operating lease liabilities		$ 2,728
Weighted-average remaining lease term - operating leases (in years)	5 years 3 months	6 years 8 months 4 days
Weighted-average discount rate - operating leases	7.875%	7.875%

Leases (Details Narrative)

Leases (Details Narrative) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Leases
Operating lease, right-of-use assets	$ 2,618	$ 4,267
Operating lease obligations	2,879	4,525
Operating lease, liability, current	499	1,565
Operating lease liability noncurrent	$ 2,380	$ 2,960

Schedule of Intangible Assets,

Schedule of Intangible Assets, Less Accumulated Amortization (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Impairment Effects on Earnings Per Share [Line Items]
Total Intangible assets	$ 70	$ 5,375
Less Accumulated Amortization	(70)	(3,951)
Intangible Assets, net		1,424
Defensive Asset [Member]
Impairment Effects on Earnings Per Share [Line Items]
Total Intangible assets		$ 2,105
Finite lived intangible asset, useful life	60 months	60 months
Laboratory Information Management Software [Member]
Impairment Effects on Earnings Per Share [Line Items]
Total Intangible assets		$ 3,200
Finite lived intangible asset, useful life	24 months	24 months
Other Infinite Lived Intangible Asset [Member]
Impairment Effects on Earnings Per Share [Line Items]
Total Intangible assets	$ 70	$ 70
Finite lived intangible asset, useful life	1 year	1 year

Intangible Assets, net (Details

Intangible Assets, net (Details Narrative) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization of intangible assets	$ 82	$ 505	$ 559	$ 1,516
Intangible assets net	0		0
Estimated future amortization expense					$ 1,424

Schedule of Financial Assets an

Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($) $ in Thousands		Sep. 30, 2024	Dec. 31, 2023
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets at fair value	[1]	$ 25,511
Total liabilities at fair value	[1]	32,050	$ 44,200
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets at fair value	[1]	25,511
Total liabilities at fair value	[1]
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets at fair value	[1]
Total liabilities at fair value	[1]
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets at fair value	[1]
Total liabilities at fair value	[1]	32,050	44,200
Lucid Common Stock [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets at fair value	[1]	25,511
Lucid Common Stock [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets at fair value	[1]	25,511
Lucid Common Stock [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets at fair value	[1]
Lucid Common Stock [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets at fair value	[1]
April 2022 Senior Convertible Note [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total liabilities at fair value	[1]	19,850	19,000
April 2022 Senior Convertible Note [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total liabilities at fair value	[1]
April 2022 Senior Convertible Note [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total liabilities at fair value	[1]
April 2022 Senior Convertible Note [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total liabilities at fair value	[1]	19,850	19,000
September 2022 Senior Convertible Note [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total liabilities at fair value	[1]	12,200	11,250
September 2022 Senior Convertible Note [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total liabilities at fair value	[1]
September 2022 Senior Convertible Note [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total liabilities at fair value	[1]
September 2022 Senior Convertible Note [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total liabilities at fair value	[1]	$ 12,200	11,250
Lucid March 2023 Senior Convertible Note [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total liabilities at fair value	[1]		13,950
Lucid March 2023 Senior Convertible Note [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total liabilities at fair value	[1]
Lucid March 2023 Senior Convertible Note [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total liabilities at fair value	[1]
Lucid March 2023 Senior Convertible Note [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total liabilities at fair value	[1]		$ 13,950
[1]There were no transfers between the respective Levels during the nine months ended September 30, 2024.

Schedule of Fair Value Assumpti

Schedule of Fair Value Assumption Used (Details) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2024 USD ($)	Dec. 31, 2023 USD ($)	Mar. 21, 2023 USD ($)	Sep. 08, 2022 USD ($)	Apr. 04, 2022 USD ($)
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Debt instrument fair value	$ 32,050	$ 44,200
Face value principal payable	25,229	37,683
April 2022 Senior Convertible Note [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Debt instrument fair value	19,850	19,000
Face value principal payable	$ 17,602	$ 17,602			$ 27,500
April 2022 Senior Convertible Note [Member] | Measurement Input Required Rate of Return [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumption measurement input	9
April 2022 Senior Convertible Note [Member] | Measurement Input Required Rate of Return [Member] | Minimum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumption measurement input		10
April 2022 Senior Convertible Note [Member] | Measurement Input Required Rate of Return [Member] | Maximum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumption measurement input		10.50
April 2022 Senior Convertible Note [Member] | Measurement Input, Conversion Price [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumption measurement input	75	75
April 2022 Senior Convertible Note [Member] | Measurement Input, Share Price [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumption measurement input	1.23	4.12
April 2022 Senior Convertible Note [Member] | Measurement Input, Expected Term [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected term years	6 months 3 days
April 2022 Senior Convertible Note [Member] | Measurement Input, Expected Term [Member] | Minimum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected term years		3 months 3 days
April 2022 Senior Convertible Note [Member] | Measurement Input, Expected Term [Member] | Maximum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected term years		1 year 3 months 3 days
April 2022 Senior Convertible Note [Member] | Measurement Input, Price Volatility [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumption measurement input	160	85
April 2022 Senior Convertible Note [Member] | Measurement Input, Risk Free Interest Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumption measurement input	4.28
April 2022 Senior Convertible Note [Member] | Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumption measurement input		4.54
April 2022 Senior Convertible Note [Member] | Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumption measurement input		5.25
April 2022 Senior Convertible Note [Member] | Measurement Input, Expected Dividend Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumption measurement input
September 2022 Senior Convertible Note [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Debt instrument fair value	$ 12,200	$ 11,250
Face value principal payable	$ 7,627	$ 9,062		$ 11,250
September 2022 Senior Convertible Note [Member] | Measurement Input Required Rate of Return [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumption measurement input	8.800
September 2022 Senior Convertible Note [Member] | Measurement Input Required Rate of Return [Member] | Minimum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumption measurement input		10
September 2022 Senior Convertible Note [Member] | Measurement Input Required Rate of Return [Member] | Maximum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumption measurement input		10.20
September 2022 Senior Convertible Note [Member] | Measurement Input, Conversion Price [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumption measurement input	75	75
September 2022 Senior Convertible Note [Member] | Measurement Input, Share Price [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumption measurement input	1.23	4.12
September 2022 Senior Convertible Note [Member] | Measurement Input, Expected Term [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected term years	11 months 8 days
September 2022 Senior Convertible Note [Member] | Measurement Input, Expected Term [Member] | Minimum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected term years		8 months 8 days
September 2022 Senior Convertible Note [Member] | Measurement Input, Expected Term [Member] | Maximum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected term years		1 year 8 months 8 days
September 2022 Senior Convertible Note [Member] | Measurement Input, Price Volatility [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumption measurement input	160	85
September 2022 Senior Convertible Note [Member] | Measurement Input, Risk Free Interest Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumption measurement input	3.95
September 2022 Senior Convertible Note [Member] | Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumption measurement input		4.31
September 2022 Senior Convertible Note [Member] | Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumption measurement input		4.96
September 2022 Senior Convertible Note [Member] | Measurement Input, Expected Dividend Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumption measurement input
Lucid March 2023 Senior Convertible Note [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Debt instrument fair value		$ 13,950
Face value principal payable		$ 11,019	$ 11,100
Lucid March 2023 Senior Convertible Note [Member] | Measurement Input Required Rate of Return [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumption measurement input		10
Lucid March 2023 Senior Convertible Note [Member] | Measurement Input, Conversion Price [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumption measurement input		5
Lucid March 2023 Senior Convertible Note [Member] | Measurement Input, Share Price [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumption measurement input		1.41
Lucid March 2023 Senior Convertible Note [Member] | Measurement Input, Expected Term [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected term years		1 year 2 months 19 days
Lucid March 2023 Senior Convertible Note [Member] | Measurement Input, Price Volatility [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumption measurement input		60
Lucid March 2023 Senior Convertible Note [Member] | Measurement Input, Risk Free Interest Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumption measurement input		4.56
Lucid March 2023 Senior Convertible Note [Member] | Measurement Input, Expected Dividend Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumption measurement input

Financial Instruments Fair Va_3

Financial Instruments Fair Value Measurements (Details Narrative) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023	Mar. 21, 2023	Sep. 08, 2022	Apr. 04, 2022
Short-Term Debt [Line Items]
Face value principal payable	$ 25,229	$ 37,683
April 2022 Senior Convertible Note [Member]
Short-Term Debt [Line Items]
Face value principal payable	17,602	17,602			$ 27,500
September 2022 Senior Convertible Note [Member]
Short-Term Debt [Line Items]
Face value principal payable	$ 7,627	9,062		$ 11,250
Lucid March 2023 Senior Convertible Note [Member]
Short-Term Debt [Line Items]
Face value principal payable		$ 11,019	$ 11,100

Summary of Outstanding Debt (De

Summary of Outstanding Debt (Details) - USD ($) $ / shares in Units, $ in Thousands			9 Months Ended	12 Months Ended
	Sep. 08, 2022	Apr. 04, 2022	Sep. 30, 2024	Dec. 31, 2023	Mar. 21, 2023
Short-Term Debt [Line Items]
Face Value Principal Outstanding			$ 25,229	$ 37,683
Fair Value			$ 32,050	$ 44,200
April 2022 Senior Convertible Note [Member]
Short-Term Debt [Line Items]
Maturity Date		Apr. 04, 2024	Apr. 04, 2025	Apr. 04, 2025
Stated Interest Rate		7.875%	7.875%	7.875%
Conversion Price		$ 75	$ 75	$ 75
Face Value Principal Outstanding		$ 27,500	$ 17,602	$ 17,602
Fair Value			$ 19,850	$ 19,000
September 2022 Senior Convertible Note [Member]
Short-Term Debt [Line Items]
Maturity Date	Sep. 06, 2024		Sep. 08, 2025	Sep. 08, 2025
Stated Interest Rate	7.875%		7.875%	7.875%
Conversion Price	$ 75		$ 75	$ 75
Face Value Principal Outstanding	$ 11,250		$ 7,627	$ 9,062
Fair Value			$ 12,200	$ 11,250
Lucid March 2023 Senior Convertible Note [Member]
Short-Term Debt [Line Items]
Maturity Date				Mar. 21, 2025
Stated Interest Rate				7.875%
Conversion Price				$ 5
Face Value Principal Outstanding				$ 11,019	$ 11,100
Fair Value				$ 13,950

Schedule of Changes in Fair Val

Schedule of Changes in Fair Value of Debt (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Short-Term Debt [Line Items]
Fair Value - Beginning of Period	$ 44,000	$ 42,990	$ 44,200	$ 33,650
Face value principal – issue date				11,111
Fair value adjustment – issue date				789
Installment repayments – common stock	(1,252)	(2,251)	(3,440)	(5,194)
Non-installment payments – common stock	(190)	(141)	(930)	(349)
Deconsolidation of Lucid Diagnostics	(10,268)		(10,268)
Change in fair value	(240)	4,392	2,488	4,983
Fair Value - Ending of Period	32,050	44,990	32,050	44,990
Other Income (Expense) - Change in fair value	240	(4,392)	(2,488)	(5,772)
April 2022 Senior Convertible Note [Member]
Short-Term Debt [Line Items]
Fair Value - Beginning of Period	19,200	19,530	19,000	22,000
Face value principal – issue date
Fair value adjustment – issue date
Installment repayments – common stock		(952)		(3,895)
Non-installment payments – common stock		(41)		(249)
Deconsolidation of Lucid Diagnostics
Change in fair value	650	863	850	1,544
Fair Value - Ending of Period	19,850	19,400	19,850	19,400
September 2022 Senior Convertible Note [Member]
Short-Term Debt [Line Items]
Fair Value - Beginning of Period	13,600	11,850	11,250	11,650
Face value principal – issue date
Fair value adjustment – issue date
Installment repayments – common stock	(455)	(1,207)	(1,435)	(1,207)
Non-installment payments – common stock	(55)	(51)	(143)	(51)
Deconsolidation of Lucid Diagnostics
Change in fair value	(890)	508	2,528	708
Fair Value - Ending of Period	12,200	11,100	12,200	11,100
Lucid March 2023 Senior Convertible Note [Member]
Short-Term Debt [Line Items]
Fair Value - Beginning of Period	11,200	11,610	13,950
Face value principal – issue date				11,111
Fair value adjustment – issue date				789
Installment repayments – common stock	(797)	(92)	(2,005)	(92)
Non-installment payments – common stock	(135)	(49)	(787)	(49)
Deconsolidation of Lucid Diagnostics	(10,268)		(10,268)
Change in fair value		3,021	(890)	2,731
Fair Value - Ending of Period		14,490		14,490
Other Income Expense [Member]
Short-Term Debt [Line Items]
Fair Value - Beginning of Period
Face value principal – issue date
Fair value adjustment – issue date				(789)
Installment repayments – common stock
Non-installment payments – common stock
Deconsolidation of Lucid Diagnostics
Change in fair value	240	(4,392)	(2,488)	(4,983)
Fair Value - Ending of Period

Debt (Details Narrative)

Debt (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands			2 Months Ended	3 Months Ended		8 Months Ended	9 Months Ended		12 Months Ended
	Sep. 08, 2022	Apr. 04, 2022	Sep. 10, 2024	Sep. 30, 2024	Sep. 30, 2023	Sep. 10, 2024	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Mar. 21, 2023	Mar. 31, 2022
Short-Term Debt [Line Items]
Principal amouint				$ 25,229			$ 25,229		$ 37,683
Conversions - Senior Secured Convertible Note				908	$ 3,989		2,021	$ 8,411
Debt extinguishment losses				1,403	$ 1,764		2,535	$ 3,032
Cash [Member]
Short-Term Debt [Line Items]
Notes payable				2,000			2,000
April 2022 Senior Convertible Note [Member]
Short-Term Debt [Line Items]
Principal amouint		$ 27,500		$ 17,602			$ 17,602		$ 17,602
Debt interest rate		7.875%		7.875%			7.875%		7.875%
Conversion price		$ 75		$ 75			$ 75		$ 75
Debt instrument maturity date, description		Apr. 04, 2024					Apr. 04, 2025		Apr. 04, 2025
Debt instrument maturity date, description		maturity date the investor agreed to extend by one year, to April 4, 2025
September 2022 Senior Convertible Note [Member]
Short-Term Debt [Line Items]
Principal amouint	$ 11,250			$ 7,627			$ 7,627		$ 9,062
Debt interest rate	7.875%			7.875%			7.875%		7.875%
Conversion price	$ 75			$ 75			$ 75		$ 75
Debt instrument maturity date, description	Sep. 06, 2024						Sep. 08, 2025		Sep. 08, 2025
Debt instrument maturity date, description	maturity date the investor agreed to extend by one year, to September 8, 2025.
Debt instrument, description							The Company is subject to financial covenants requiring: (i) a minimum of $8.0 million of available cash at all times; (ii) the ratio of (a) the outstanding principal amount of the total senior convertible notes outstanding, accrued and unpaid interest thereon and accrued and unpaid late charges to (b) the Company’s average market capitalization over the prior ten trading days, to not exceed 30% (the “Debt to Market Cap Ratio Test”); and (iii) the Company’s market capitalization to at no time be less than $75 million
Repayment for debt				$ 455			$ 1,435
Interest expense				$ 55			$ 143
Conversions - Senior Secured Convertible Note, shares				509,942			1,084,366
Gain (loss) on extinguishment of debt				$ 1,050			$ 1,501
September 2022 Senior Convertible Note [Member] | Interest Rate Floor [Member]
Short-Term Debt [Line Items]
Gain (loss) on extinguishment of debt				652			1,059
Acceleration floor payments				$ 652			$ 652
April 2022 Senior Convertible Note and September 2022 Senior Convertible Note [Member]
Short-Term Debt [Line Items]
Debt interest rate				82.50%			82.50%
Senior convertible note							1,000,000
Conversion price per share				$ 2.70			$ 2.70
April 2022 Senior Convertible Note and September 2022 Senior Convertible Note [Member] | June 30, 2024 Through September 03, 2024 [Member]
Short-Term Debt [Line Items]
Conversion price				$ 0.40			$ 0.40
Lucid March 2023 Senior Convertible Note [Member]
Short-Term Debt [Line Items]
Principal amouint									$ 11,019	$ 11,100
Debt interest rate									7.875%
Conversion price									$ 5
Debt instrument maturity date, description									Mar. 21, 2025
Repayment for debt						$ 2,005
Conversions - Senior Secured Convertible Note, shares						4,172,002
Gain (loss) on extinguishment of debt			$ 328			$ 1,009
Debt Instrument, Periodic Payment, Interest						787
Investor [Member] | September 2022 Senior Convertible Note [Member]
Short-Term Debt [Line Items]
Conversions - Senior Secured Convertible Note				$ 907			$ 2,002
Investor [Member] | Lucid March 2023 Senior Convertible Note [Member]
Short-Term Debt [Line Items]
Conversions - Senior Secured Convertible Note						$ 3,801
Securities Purchase Agreement [Member] | Accredited Institutional Investor [Member]
Short-Term Debt [Line Items]
Principal amouint											$ 50,000
Securities Purchase Agreement [Member] | Accredited Institutional Investor [Member] | Initial Issuance [Member]
Short-Term Debt [Line Items]
Principal amouint											27,500
Securities Purchase Agreement [Member] | Accredited Institutional Investor [Member] | Additional Issuance [Member]
Short-Term Debt [Line Items]
Principal amouint											$ 22,500

Schedule of Summarizes Informat

Schedule of Summarizes Information About Stock Options (Details) - USD ($) $ / shares in Units, $ in Thousands		9 Months Ended		12 Months Ended
		Sep. 30, 2024		Dec. 31, 2023
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Stock Options Outstanding, Ending Balance		66,720
2014 Equity Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Stock Options Outstanding, Beginning Balance		1,192,458
Weighted Average Exercise Price, Beginning Balance		$ 26.18
Remaining Contractual Term (Years), Ending Balance		5 years 10 months 24 days	[1]	7 years 3 months 18 days
Intrinsic Value Outstanding, Beginning Balance	[2]
Number of Stock Options, Granted	[3]	79,500
Weighted Average Exercise Price, Granted	[3]	$ 2.28
Number of Stock Option, Exercised
Weighted Average Exercise Price, Exercised
Number of Stock Option, Forfeited		(38,851)
Weighted Average Exercise Price, Forfeited		$ 13.47
Number of Stock Options Outstanding, Ending Balance		1,233,107	[1]	1,192,458
Weighted Average Exercise Price, Ending Balance		$ 25.04	[1]	$ 26.18
Intrinsic Value Outstanding, Ending Balance	[2]		[1]
Number of Stock Options Vested and exercisable stock options		956,977
Weighted Average Exercise Price, Vested and exercisable stock options		$ 30.27
Remaining Contractual Term (Years), Vested and exercisable stock options		5 years 1 month 6 days
Intrinsic Value Exercisable, Ending Balance	[2]
2018 Equity Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Stock Options Outstanding, Beginning Balance		5,504,383
Weighted Average Exercise Price, Beginning Balance		$ 2
Remaining Contractual Term (Years), Ending Balance		8 years 3 months 18 days	[4]	8 years 6 months
Intrinsic Value Outstanding, Beginning Balance	[5]	$ 765
Number of Stock Options, Granted	[6]	3,604,000
Weighted Average Exercise Price, Granted	[6]	$ 1.22
Number of Stock Option, Exercised		(3,333)
Weighted Average Exercise Price, Exercised		$ 1.31
Number of Stock Option, Forfeited		(417,501)
Weighted Average Exercise Price, Forfeited		$ 1.63
Number of Stock Options Outstanding, Ending Balance		8,687,549	[4]	5,504,383
Weighted Average Exercise Price, Ending Balance		$ 1.69	[4]	$ 2
Intrinsic Value Outstanding, Ending Balance	[5]	$ 191	[4]	$ 765
Number of Stock Options Vested and exercisable stock options		3,084,682
Weighted Average Exercise Price, Vested and exercisable stock options		$ 2.25
Remaining Contractual Term (Years), Vested and exercisable stock options		7 years 1 month 6 days
Intrinsic Value Exercisable, Ending Balance	[5]	$ 191
[1]The outstanding stock options presented in the table above are inclusive of 60,054 523,300 The intrinsic value is computed as the difference between the quoted price of the Lucid Diagnostics common stock on each of September 10, 2024 and December 31, 2023 and the exercise price of the underlying Lucid Diagnostics stock options, to the extent such quoted price is greater than the exercise price.

Schedule of Summarizes Inform_2

Schedule of Summarizes Information About Stock Options (Details) (Parenthetical) - shares		9 Months Ended	12 Months Ended
	Sep. 10, 2024	Sep. 30, 2024	Dec. 31, 2023
2018 Equity Plan [Member] | Lucid Diagnostics Inc [Member]
Number of stock options granted. shares	523,300		523,300
Parent Company [Member] | 2014 Equity Plan [Member]
Number of stock options granted. shares		60,054	60,054

Schedule of Restricted Stock Aw

Schedule of Restricted Stock Award Activity (Details) - Restricted Stock Units (RSUs) [Member]	9 Months Ended
	Sep. 30, 2024 $ / shares shares
2014 Equity Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Restricted Stock Awards, Unvested restricted stock awards, Beginning balance | shares	70,527
Weighted Average Grant Date Fair Value, Unvested restricted stock awards, Beginning balance | $ / shares	$ 38.77
Number of Restricted Stock Awards, Granted | shares	390,000
Weighted Average Grant Date Fair Value, Granted | $ / shares	$ 1.85
Number of Restricted Stock Awards, Vested | shares	(135,080)
Weighted Average Grant Date Fair Value, Vested | $ / shares	$ 2
Number of Restricted Stock Awards, Forfeited | shares
Weighted Average Grant Date Fair Value, Forfeited | $ / shares
Number of Restricted Stock Awards, Unvested restricted stock awards, Ending balance | shares	325,447
Weighted Average Grant Date Fair Value, Unvested restricted stock awards, Ending balance | $ / shares	$ 9.79
2018 Equity Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Restricted Stock Awards, Unvested restricted stock awards, Beginning balance | shares	2,337,440
Weighted Average Grant Date Fair Value, Unvested restricted stock awards, Beginning balance | $ / shares	$ 8.99
Number of Restricted Stock Awards, Granted | shares	1,600,000
Weighted Average Grant Date Fair Value, Granted | $ / shares	$ 1.03
Number of Restricted Stock Awards, Vested | shares	(26,912)
Weighted Average Grant Date Fair Value, Vested | $ / shares	$ 4.56
Number of Restricted Stock Awards, Forfeited | shares	(13,088)
Weighted Average Grant Date Fair Value, Forfeited | $ / shares	$ 4.56
Number of Restricted Stock Awards, Unvested restricted stock awards, Ending balance | shares	3,897,440
Weighted Average Grant Date Fair Value, Unvested restricted stock awards, Ending balance | $ / shares	$ 5.77

Schedule of Stock-Based Compens

Schedule of Stock-Based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Total stock-based compensation expense	$ 1,931	$ 2,245	$ 5,716	$ 9,171
Cost Of Revenue [Member]
Total stock-based compensation expense	32	32	112	86
Selling and Marketing Expense [Member]
Total stock-based compensation expense	292	403	1,082	1,302
General and Administrative Expense [Member]
Total stock-based compensation expense	1,426	1,499	3,717	6,761
Research and Development Expense [Member]
Total stock-based compensation expense	$ 181	$ 311	$ 805	$ 1,022

Schedule of Stock-Based Compe_2

Schedule of Stock-Based Compensation Expense Recognized by Lucid Diagnostics (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Total stock-based compensation expense	$ 1,931	$ 2,245	$ 5,716	$ 9,171
Lucid Diagnostics Inc [Member]
Total stock-based compensation expense	955	1,252	3,089	5,859
Cost Of Revenue [Member]
Total stock-based compensation expense	32	32	112	86
Selling and Marketing Expense [Member]
Total stock-based compensation expense	292	403	1,082	1,302
General and Administrative Expense [Member]
Total stock-based compensation expense	1,426	1,499	3,717	6,761
Research and Development Expense [Member]
Total stock-based compensation expense	181	311	805	1,022
Lucid Diagnostics 2018 Equity Plan [Member] | Cost Of Revenue [Member]
Total stock-based compensation expense	24	16	81	44
Lucid Diagnostics 2018 Equity Plan [Member] | Selling and Marketing Expense [Member]
Total stock-based compensation expense	252	228	849	697
Lucid Diagnostics 2018 Equity Plan [Member] | General and Administrative Expense [Member]
Total stock-based compensation expense	548	721	1,484	4,069
Lucid Diagnostics 2018 Equity Plan [Member] | Research and Development Expense [Member]
Total stock-based compensation expense	98	67	356	204
PAVmed Inc 2014 Equity Plan [Member] | Cost Of Revenue [Member]
Total stock-based compensation expense	9	10	30	26
PAVmed Inc 2014 Equity Plan [Member] | Selling and Marketing Expense [Member]
Total stock-based compensation expense	18	106	136	359
PAVmed Inc 2014 Equity Plan [Member] | General and Administrative Expense [Member]
Total stock-based compensation expense	1	7	5	170
PAVmed Inc 2014 Equity Plan [Member] | Research and Development Expense [Member]
Total stock-based compensation expense	$ 5	$ 97	$ 148	$ 290

Schedule of Unrecognized Compen

Schedule of Unrecognized Compensation Expense (Details) - PAVmed Inc 2014 Equity Plan [Member] $ in Thousands	9 Months Ended
	Sep. 30, 2024 USD ($)
Equity Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Unrecognized Expense	$ 1,377
Weighted Average Remaining Service Period	1 year 6 months
Restricted Stock [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Unrecognized Expense	$ 397
Weighted Average Remaining Service Period	2 years 2 months 12 days

Schedule of Fair Values of Stoc

Schedule of Fair Values of Stock Options Granted Using Black-scholes Valuation Model Assumptions (Details)	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
2014 Equity Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Expected term of stock options (in years)	5 years 9 months 18 days	5 years 8 months 12 days
Expected stock price volatility	90%	88%
Risk free interest rate	4.30%	3.70%
Expected dividend yield
2018 Equity Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Expected term of stock options (in years)	5 years 8 months 12 days	5 years 7 months 6 days
Expected stock price volatility	73%	75%
Risk free interest rate		3.70%
Expected dividend yield

Stock-Based Compensation (Detai

Stock-Based Compensation (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands			1 Months Ended		3 Months Ended		9 Months Ended
		Feb. 22, 2024	May 31, 2024	Jan. 31, 2024	Mar. 31, 2024	Mar. 31, 2023	Sep. 30, 2024		Sep. 30, 2023	Dec. 31, 2023
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of stock options outstanding							66,720
Proceeds from common stock							$ 1,268		$ 1,166
Employee Stock Purchase Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Common stock capital shares reserved for future issuance							300,001
Increase in available for grant							139,863
Number of common stock purchased					34,332	38,216			20,267
Proceeds from common stock					$ 62	$ 182			$ 76
Treasury stock						12,590
Increase in reserve stock				166,667
Employee Stock Purchase Plan [Member] | Lucid Diagnostics Inc [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of common stock purchased					511,884	231,987			276,213
Proceeds from common stock					$ 353	$ 276			$ 275
2014 Equity Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Common stock capital shares reserved for future issuance							1,835,970
Increase in available for grant				432,452			79,321
Number of stock options outstanding							1,233,107	[1]		1,192,458
Granted	[2]						79,500
Weighted average fair value of stock options							$ 1.47		$ 5.25
2014 Equity Plan [Member] | Parent Company [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Granted		59,500
Weighted average exercise price		$ 1.85
2014 Equity Plan [Member] | Parent Company [Member] | Restricted Stock [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Granted		390,000
Aggregate fair value		$ 700
2018 Equity Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of stock options outstanding							8,687,549	[3]		5,504,383
Granted	[4]						3,604,000
Weighted average fair value of stock options							$ 0.79		$ 0.88
2018 Equity Plan [Member] | Lucid Diagnostics Inc [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Granted		2,895,000
Weighted average exercise price		$ 1.25
2018 Equity Plan [Member] | Restricted Stock [Member] | Lucid Diagnostics Inc [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Granted			1,600,000
Aggregate fair value			$ 1,500
[1]The outstanding stock options presented in the table above are inclusive of 60,054 523,300

Preferred Stock (Details Narrat

Preferred Stock (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended	3 Months Ended				6 Months Ended		9 Months Ended		12 Months Ended
	Nov. 30, 2024	Sep. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Mar. 31, 2023	Jun. 30, 2024	Jun. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
Class of Stock [Line Items]
Preferred stock stated value per share		$ 0.001						$ 0.001		$ 0.001
Dividends earned		$ 83		$ 77				$ 244	$ 226
Aggregate preferred stock dividends earned
Series B Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock shares outstanding		1,385,149						1,385,149		1,305,213
Preferred stock stated value per share		$ 0.001						$ 0.001		$ 0.001
Preferred stock stated value per share		$ 3						$ 3
Dividend rate percentage								8%
Dividends earned		$ 83		$ 77				$ 244	226
Aggregate preferred stock dividends declared								$ 239	$ 221
Series B Convertible Preferred Stock [Member] | Subsequent Event [Member]
Class of Stock [Line Items]
Aggregate preferred stock dividends earned	$ 83
Additioanal aggregate shares of convertible preferred stock	27,716
Series B Convertible Preferred Stock [Member] | Board Of Directors [Member]
Class of Stock [Line Items]
Aggregate preferred stock dividends earned			$ 80		$ 74	$ 81	$ 75			$ 78	$ 72
Additioanal aggregate shares of convertible preferred stock			26,640		24,610	27,173	25,104	79,936	73,842	26,123	24,128

Common Stock and Common Stock_2

Common Stock and Common Stock Purchase Warrants (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands						1 Months Ended	3 Months Ended	9 Months Ended
	Mar. 07, 2024	Feb. 15, 2024	Jan. 15, 2024	Dec. 07, 2023	Nov. 28, 2023	Feb. 28, 2023	Sep. 30, 2024	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Accumulated Other Comprehensive Income (Loss) [Line Items]
Reverse stock split					1-for-15
Common stock, shares authorized							50,000,000	50,000,000		50,000,000
Stock Issused and outstanding description				every 15 shares of the Company’s common stock that were issued and outstanding were automatically combined into one issued and outstanding share, without any change in par value of such shares.
Debt instrument fee description	On March 7, 2024, the Company received a notice from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) stating that, for the prior 30 consecutive business days (through March 6, 2024), the market value of the Company’s listed securities had been below the minimum of $35 million required for continued inclusion on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(2). The Company was provided 180 calendar days, or until September 3, 2024, to regain compliance with the rule. The Company did not regain compliance with the rule during the allotted time period. Accordingly, on September 10, 2024, the Company received a staff determination letter from the Nasdaq Listing Qualifications Department, stating that unless the Company timely requested a hearing before a Nasdaq Hearings Panel (the “Panel”) to appeal the staff determination, the Company’s securities would be subject to suspension and delisting. The Company timely requested a hearing before the Panel, which was held on October 29, 2024.
At-the-market equity facility, shares								627,302
At-the-market equity facility, value								$ 977
Payments for commissions percentage								3%
Issued for services							$ 150	$ 601	$ 747
Warrant price decrease		$ 0.52
Share price		0.37709668
Exercise price		$ 23.48
Series Z Warrants [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Exercise price							$ 23.48	$ 23.48		$ 23.48
Class of Warrant or Right, Outstanding							11,937,450	11,937,450		11,937,450
Purchase of warrants							795,830	795,830		795,830
Exercise price, post reverse-split							$ 24	$ 24		$ 24
Lucid Diagnostics Inc [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Common stock, dividends shares		3,331,747	38
Vendors [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares issued								200,809
Issued for services								$ 200
Common Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares issued							171,052	200,809	100,000
Issued for services
Common Stock [Member] | Lucid Diagnostics Inc [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Common stock, dividends shares			100
April 2022 Senior Convertible Note and September 2022 Senior Convertible Note [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Convertible common stock shares issued upon conversion							574,424	574,424
Debt Instrument, Convertible, If-converted Value in Excess of Principal								$ 980
Employee Stock Purchase Plan [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of common stock issued								34,332
Minimum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Reverse stock split						1-for-5
Common stock, shares authorized						50,000,000
Minimum [Member] | Series Z Warrants [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Exercise price, post reverse-split							$ 0.52	$ 0.52		$ 0.52
Maximum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Reverse stock split						1-for-15
Common stock, shares authorized						250,000,000

Schedule of Noncontrolling Inte

Schedule of Noncontrolling Interest of Stockholders' Equity (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Noncontrolling Interest [Abstract]
NCI – equity - December 31, 2023			$ 29,813
Net loss attributable to NCI	$ (3,688)	$ (4,079)	(11,075)	$ (11,716)
Impact of subsidiary equity transactions			(4,414)
Lucid Diagnostics proceeds from issuance of preferred stock Series A-1			5,670
Lucid Diagnostics exchange of preferred stock Series A and Series A-1			(24,294)
Lucid Diagnostics issuance through exchange - Series B and Series B-1			31,790
Lucid Diagnostics issuance through sale - Series B and Series B-1			24,129
Lucid Diagnostics deemed dividend on preferred stock			(7,496)
Lucid Diagnostics issuance of common stock for settlement of vendor service agreement			401
Lucid Diagnostics 2018 Equity Plan stock option exercise			4
Lucid Diagnostics Employee Stock Purchase Plan Purchase			353
Conversion of Lucid Diagnostics common stock for Senior Secured Convertible Debt			3,801
Stock-based compensation expense - Lucid Diagnostics 2018 Equity Plan			2,771
Stock-based compensation expense - Veris Health 2021 Equity Plan			368
Deconsolidation of Lucid			(56,339)
NCI – equity - September 30, 2024	$ (4,518)		$ (4,518)

Schedule of Net Loss Attributab

Schedule of Net Loss Attributable to Common Stockholders (Details) $ in Thousands	Mar. 13, 2024 USD ($)
Noncontrolling Interest [Abstract]
Fair Value - 31,790 shares of Lucid Series B Preferred Stock issued in exchange for Lucid Series A and Lucid Series A-1 Preferred Stock	$ 31,790
Less: Carrying value related to Lucid Series A and Lucid Series A-1 Preferred Stock Exchanged for Lucid Series B Preferred Stock (of 24,295 shares)	(24,294)
Deemed Dividend Charged to Accumulated Deficit	$ 7,496

Schedule of Net Loss Attribut_2

Schedule of Net Loss Attributable to Common Stockholders (Details) (Parenthetical)	Mar. 13, 2024 shares
Noncontrolling Interest [Abstract]
Fair value of the consideration shares	31,790
Less carrying value related to series and series A1 preferred stock exchanged for series B preferred stock shares	24,295

Noncontrolling Interest (Detail

Noncontrolling Interest (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands								9 Months Ended
	Sep. 10, 2024	May 06, 2024	Mar. 13, 2024	Feb. 15, 2024	Jan. 26, 2024	Jan. 15, 2024	Mar. 07, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Noncontrolling Interest [Line Items]
Common stock shares outstanding								10,660,394		8,578,505
Issuance of shares, stated value								$ 0.001		$ 0.001
Gross proceeds								$ 29,798	$ 13,625
Carrying value								$ 24,294
Series A Convertible Preferred Stock [Member]
Noncontrolling Interest [Line Items]
Number of shares issued							13,625
Issuance of shares, stated value							$ 1,000
Preferred shares conversion price							$ 1.394
Dividend percentage							20%
Sale of stock, transaction value							$ 13,625
Series A-1 Preferred Stock [Member]
Noncontrolling Interest [Line Items]
Number of shares issued			5,670
Gross proceeds			$ 5,670
Series B Convertible Preferred Stock [Member]
Noncontrolling Interest [Line Items]
Number of shares issued			44,285
Issuance of shares, stated value								$ 0.001		$ 0.001
Dividend percentage								8%
Conversion price			$ 1.2444
Gross proceeds, sale of shares			$ 18,100
Fair value of the consideration shares			31,790
Carrying value			$ 24,294
Fair value of deemed dividend			$ 7,500
Lucid Series A and Lucid Series A-1 Preferred Stock [Member]
Noncontrolling Interest [Line Items]
Outstanding shares, percentage			100%
Series B 1 Preferred Stock [Member]
Noncontrolling Interest [Line Items]
Number of shares issued		11,634
Conversion price		$ 0.7228
Gross proceeds, sale of shares		$ 11,600
Lucid Diagnostics Inc [Member]
Noncontrolling Interest [Line Items]
Common stock shares issued								51,597,718
Common stock shares outstanding								51,597,718
Partners capital account units acquisitions								31,302,444
Partners capital account units description	On September 10, 2024, following preferred equity transactions completed by Lucid earlier in 2024 and the termination of voting proxies entered into between PAVmed and certain shareholders of Lucid, PAVmed’s voting interest in the Company was reduced to less than 50.0%, resulting in the loss of a controlling financial interest. However, PAVmed retains the ability to exercise significant influence over Lucid. Upon deconsolidation, the Company’s ownership of 31,302,444 shares of Lucid Diagnostics common stock was valued at $25.1 million, which resulted in a gain on deconsolidation of $72.3 million in the accompanying unaudited condensed consolidated statements of operations for the three and nine months ended September 30, 2024.
Received from payment of fees					$ 4,675
Number of shares issued					3,331,771
Common stock, dividends shares				3,331,747		38

Schedule of Comparison of Basic

Schedule of Comparison of Basic and Fully Diluted Net Loss Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands		3 Months Ended		9 Months Ended
		Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Earnings Per Share [Abstract]
Net income (loss) - before noncontrolling interest		$ 60,711	$ (21,750)	$ 27,285	$ (61,855)
Net income (loss) attributable to noncontrolling interest		3,688	4,079	11,075	11,716
Net income (loss) - as reported, attributable to PAVmed Inc.		64,399	(17,671)	38,360	(50,139)
Series B Convertible Preferred Stock dividends – earned		(83)	(77)	(244)	(226)
Deemed dividend on Subsidiary Preferred Stock attributable to the noncontrolling interests				(7,496)
Net income (loss) attributable to PAVmed Inc. common stockholders used in basic EPS calculation		64,316	(17,748)	30,620	(50,365)
Fair Value Adjustment for diluted EPS calculation		(240)		3,378
Net income (loss) attributable to PAVmed Inc. common stockholders used in dilutive EPS calculation		$ 64,076	$ (17,748)	$ 33,998	$ (50,365)
Weighted average common shares outstanding, basic		10,005,379	7,462,751	9,286,999	6,967,764
Weighted average common shares outstanding, diluted		44,475,638	7,462,751	43,069,449	6,967,764
Net income (loss) per share attributable to PAVmed Inc. common stockholders, basic	[1]	$ 6.43	$ (2.38)	$ 3.30	$ (7.23)
Net income (loss) per share attributable to PAVmed Inc. common stockholders, diluted	[1]	$ 1.44	$ (2.38)	$ 0.79	$ (7.23)
[1]- Convertible preferred stock and restricted stock awards would potentially be considered a participating security under the two-class method of calculating net income (loss) per share. For periods where losses are presented, such holders are not contractually obligated to share in the losses, there is no impact on the Company’s net income (loss) per share calculation for the periods indicated.

Schedule of Antidilutive Securi

Schedule of Antidilutive Securities Excluded from Computation of Diluted Earnings Per Share (Details) - shares	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	2,028,937	2,090,297
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	1,233,107	1,138,632
Restricted Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total		70,528
Series Z Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	795,830	795,830
Series B Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total		85,307

Net Income (Loss) Per Share (De

Net Income (Loss) Per Share (Details Narrative) - shares	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
2014 Equity Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Issue common stock - PAVM ATM Facility, shares	60,054	33,391